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Abstract 
Background: Dementia in older adults with Down’s syndrome is common. 
People with Down’s syndrome often have specific cognitive deficits, affecting 
prefrontal, hippocampal and cerebellar regions. A cognitive assessment 
battery has been developed (called the Arizona Cognitive Test Battery, 
ACTB), which assesses cognitive function in these areas. These tests have 
not yet been validated in older adults with Down’s syndrome. 
Methods: This study aimed to assess the use of the ACTB in older adults 
with Down’s syndrome and establish its validity in testing for dementia. 
Participants with Down’s syndrome aged 45 and over were assessed. 
Participants took part in a 2-3 hour assessment which included   tests on a 
touchscreen computer tablet as well as standard table-top tests.  
Results: 50 participants with Down’s syndrome were recruited. Of these, 19 
had a diagnosis of dementia or possible dementia. Most participants were 
able to attempt most of the tasks, although some tasks had a large number of 
participants at floor. There were significant differences between the dementia 
and no dementia groups on CANTAB Simple Reaction Time, Verbal Fluency 
and Object Memory tasks.  
Conclusions: In general, most of the tasks in the ACTB can be used in older 
adults with Down’s syndrome and have mild to moderate concurrent validity 
when compared to tabletop tests and carer ratings, although this varies on a 
test by test basis. Although, the ACTB can be used in older adults with 
Down’s syndrome, it has not been shown to clearly detect differences 
between people with Down’s syndrome who have early stage dementia and 
those who do not have dementia. Suggestions are made regarding which of 
the tests assessed in this study are most useful when assessing cognitive 
skills in older people with Down’s syndrome. It is hoped that this research will 
help in the development of appropriate cognitive tests for older adults with 
Down’s syndrome.  
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Chapter 1. Background 
1.1 Overview 
In this chapter, I will begin by defining the terminology and definitions that I 
will be using in this thesis. I will go on to discuss the epidemiology, aetiology 
and physical characteristics of Down’s syndrome, before summarising the 
relevant literature on the cognitive profile of Down’s syndrome. I will then 
consider the epidemiology, aetiology, cognitive profile and clinical features of 
dementia in Down’s syndrome. I will conclude by discussing some of the 
most common measures used to assess the cognitive deficits that may be 
associated with dementia in people with Down’s syndrome, which is the basis 
of this research study. 
1.2 Abbreviations 
ACTB - Arizona Cognitive Test Battery. This is a battery of several tests that 
has been developed to measure specific cognitive skills in people with 
Down’s syndrome. 
APO-E – Apolipoprotein E 
APP – Amyloid Precursor Protein. This is a protein that is associated with the 
development of Alzheimer’s disease. 
BP – Blood Pressure 
BPM – beats per minute (relating to pulse measurement) 
BRI – Behavioural Regulation Index (a subscale on the BRIEF) 
BRIEF – Behaviour Rating Inventory of Executive Function. This is a carer 
rated assessment of executive function. 
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CANTAB – Cambridge Neuropsychological Test Automated Battery. These 
are a set of computer-based neuropsychological tests designed to test 
specific cognitive skills. 
CAMCOG-DS – Cambridge Cognitive Examination – Down’s Syndrome 
CI – Confidence Interval 
CVA – Cerebro-Vascular Accident.  
DAT – Dementia of Alzheimer’s Type. This is a term often used to describe 
Alzheimer’s disease in individuals with Down’s syndrome.  
DLD – Dementia Questionnaire for people with Learning Disabilities. This 
was formerly known as the Dementia Questionnaire for persons with Mental 
Retardation (DMR). 
DSM – Diagnostic and Statistical Manual of Mental Disorders. 
Operationalised criteria for the diagnosis of mental disorders published by the 
American Psychiatric Association. 
DVT – Deep Vein Thrombosis 
GP – General Practitioner 
GWAS – Genome Wide Association Studies 
ICD – International Classification of Diseases. Operationalised criteria for the 
classification of diseases published by the World Health Organisation. 
IED – Intra-Extra Dimensional Shift task (one of the CANTAB 
neuropsychological tests) 
IQ – Intelligence Quotient. This is often used as a measure of general 
intelligence. 
K-BIT – Kaufman Brief Intelligence Test 
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MOT – Motor Screening Task (one of the CANTAB neuropsychological tests) 
NAID – Neuropsychological Assessment of age related cognitive deficits for 
people with Intellectual Disability. 
NEPSY - developmental NEuroPSYchological assessment. A battery of tests 
of cognitive abilities designed for children.  
NHS – National Health Service 
PAL – Paired Associates Learning task (one of the CANTAB 
neuropsychological tests) 
PAS-ADD – Psychiatric Assessment Schedule for Adults with Developmental 
Disabilities 
PICALM – Phosphatidylinositol binding Clathrin Assembly Protein. The gene 
for this protein has been shown to affect age of onset of dementia in people 
with Down’s syndrome. 
SD – Standard deviation 
SPSS – Statistical Package for the Social Sciences 
SRT – Simple Reaction Time task (one of the CANTAB neuropsychological 
tests) 
STM – Short Term Memory (a subscale on the DLD) 
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1.3 Terminology and definitions 
Cognition The word cognition is used by many different disciplines, including 
psychiatry, psychology, linguistics and computer science, and can have 
different meanings according to the context. Dierssen has recently described 
cognition as “the process or processes whereby an organism gains 
knowledge or becomes aware of events or objects in its environment and 
uses that knowledge for comprehension and problem solving” (Dierssen, 
2012). In this thesis, I have used Dierssen’s description of cognition, which 
encompasses processes such as attention, perception, calculation, 
reasoning, learning and memory. 
Dementia is characterised by a decline, from baseline functioning, in 
memory and other cognitive and daily living skills. In ICD-10, a decline in 
emotional control, motivation or social behaviour is also required for a 
diagnosis (World Health Organisation, 1992). 
Both ICD-10 (World Health Organisation, 1992) and DSM-IV (American 
Psychiatric Association, 2000) use the term dementia. In DSM 5, a new 
category of Major Neurocognitive Disorder, is used to describe dementia and 
its aetiological sub-types (American Psychiatric Association, 2013). As this 
study was conducted when ICD-10 and DSM-IV were in use, I will be using 
the ICD-10 and DSM-IV definitions of dementia in this thesis.  
Alzheimer’s disease is a type of dementia which can present insidiously 
with a decline in memory, with subsequent gradual deterioration of brain 
functions, including decline in other cognitive skills. 
Intellectual disability is defined by a significant impairment in both 
intellectual and adaptive functioning, which has arisen within the 
developmental period (i.e. before the age of 18) (World Health Organisation, 
1992). In the UK, it can be known as learning disability. Intellectual disability 
has previously been known as mental retardation or mental handicap. Both 
ICD-10 and DSM-IV use the term mental retardation, although in both 
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research and clinical practice, this term is no longer commonly used. In DSM 
5, the terminology has changed to Intellectual Disability (Intellectual 
Developmental Disorder).  
Incidence is a term given to the number of new cases of a disease or 
disorder in a population within a given time period. 
Prevalence is a term given to the number of cases of a disease or disorder 
in a population. 
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1.4 Introduction 
Over the past century, improvements in health and social care have 
enhanced the quality of life and life expectancy for the general population as 
well as for people with intellectual disability. In the 1930s, the mean life 
expectancy of people with intellectual disability was estimated at 18.5 years 
of age, which increased to 66 years of age by the 1990s (Braddock, 1999). 
Improvements in medical care, in particular cardiac surgery, have led to a 
substantial rise in the estimated life expectancy for people with Down’s 
syndrome. For example, in the USA, it has been estimated that the median 
age at death of people with Down’s syndrome with additional congenital heart 
defects increased from 0 to 18 years or more in the early 1990’s (Yang et al, 
2002) and it has been estimated that the number of people with Down’s 
syndrome in the Netherlands over 40 years old has doubled since 1990, to 
reach a peak of around 4600 in 2010 (de Graaf et al, 2011).   
People with Down’s syndrome are therefore now much more likely to be  
living into older adulthood. This  is associated with increased rates of age-
related conditions, including dementia, which, in turn may impact not only the 
individual affected, but also may have social, financial and emotional 
consequences for families, carers and other social support systems, e.g. 
local and national level healthcare and social welfare systems (Strydom and 
Sinai, 2014). 
Making a diagnosis of dementia in a person with Down’s syndrome can be 
particularly challenging, especially if a baseline level of cognitive functioning 
has not been well documented, as an important characteristic of dementia is 
a decline from baseline function (Strydom and Sinai, 2014). Although many 
of the causes and features of dementia in people with Down’s syndrome are 
similar to that of Alzheimer’s disease in the general population, there are 
some differences, for example, dementia in people with Down’s syndrome is 
more likely to present with frontal lobe related features (Ball et al, 2006a) and 
is associated with a higher rate of epilepsy. For this reason, the term 
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Dementia of Alzheimer’s type (abbreviated to DAT) is often used to describe 
Alzheimer’s disease in individuals with Down’s syndrome. 
It is still not entirely clear why adults with Down’s syndrome have such a high 
risk of developing dementia, and there is ongoing research to try to identify 
more of the risk and preventative factors. The most accepted hypothesis is 
that it is related to the amyloid precursor protein (APP) gene, which is located 
on Chromosome 21 and therefore triplicated in people with Trisomy 21 
(Rumble et al, 1989). 
By understanding more about dementia in Down’s syndrome, we hope to 
also be able to understand more about dementia in the general population. I 
will discuss Down’s syndrome and dementia in further detail in the remainder 
of this chapter. 
1.5 Down’s syndrome 
1.5.1 Epidemiology 
Down’s syndrome is the most common genetic cause of intellectual disability 
and, in the USA, has been estimated to have a rate of approximately 14 per 
10,000 live births (Parker et al, 2010). Down’s syndrome, first described by 
Langdon Down in 1866 (Down, 1866), is associated with a number of 
characteristic features, including characteristic facial features and a number 
of physical health problems, such as heart defects, thyroid problems and 
gastrointestinal and immunological disorders.   
1.5.2 Aetiology 
The most common cause of Down’s syndrome is trisomy of Chromosome 21, 
which accounts for around 95% of cases (Bull et al, 2011). This often arises 
de novo (i.e. with no previous genetic predisposition) and is caused by a non-
dysjunction in meiosis I or II (Ghosh et al, 2009). This is most often a result of 
a maternal non-dysjunction, and risk increases with increasing maternal age.  
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The other 5% of cases are translocations or mosaicisms. The most common 
translocation occurs when the long arm of Chromosome 21 is translocated 
on to the long arm of Chromosome 14. About 75% of these translocations 
arise de novo, with the remaining 25% being familial (Bull et al, 2011). In 
mosaic Down’s syndrome, not all cells carry the trisomy. Mosaic Down’s 
syndrome occurs when a trisomy 21 develops in some but not all of the cell 
lines. Individuals with a mosaicism may have a less characteristic phenotype 
than those with the full trisomy (Devlin and Morrison, 2004), although this is 
not always the case (Bull et al, 2011). 
Down’s syndrome is therefore a syndrome of increased gene dosage rather 
than caused by faulty or missing genes. The genotype of Down’s syndrome 
is complicated and further research is required to identify which parts of the 
genotype contribute to specific phenotypic characteristics (Lyle et al, 2009). 
1.5.3 Physical characteristics 
Down’s syndrome is associated with a characteristic facial appearance and a 
number of physical health conditions. Typical facial features of people with 
Down’s syndrome include oblique eye fissures, epicanthic eye folds, a flat 
nasal bridge and brachycephaly (a short, broad head) (Jackson et al, 1976). 
Adults with Down’s syndrome are often short in stature and are more likely to 
be overweight or obese. They also often have hypotonia and a lower blood 
pressure and pulse rate. 
Congenital heart defects are seen in approximately 45% of children born with 
Down’s syndrome (Freeman et al, 1998) and may require surgical correction 
at a young age. Other conditions associated with Down’s syndrome include 
gastrointestinal and endocrine problems, with 4-18% of people with Down’s 
syndrome having thyroid disease (Murphy et al, 2008; Chen et al, 2007). 
Other immunological and autoimmune diseases are also common and 
include susceptibility to infection and skin conditions such as psoriasis. Blood 
problems associated with Down’s syndrome can include polycythaemia in 
newborns, acute myeloid leukaemia and acute lymphoblastic leukaemia in 
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children and macrocytosis (Roizen and Patterson, 2003). People with Down’s 
syndrome have high rates of sleep apnoea (Chen et al, 2013), which may go 
undetected. 
People with Down’s syndrome are also more likely to have sensory 
problems: between 38% and 78% may have hearing problems and the 
prevalence of visual problems increases with age, from 38% in children 
under 1 year of age to 80% in children aged 5 – 12 years of age (Roizen and 
Patterson, 2003). 
1.5.4 Behavioural phenotype 
It is commonly believed that the behavioural phenotype of people with 
Down’s syndrome is that they are friendly and sociable. Although a number 
of people with Down’s syndrome may have these behavioural characteristics, 
challenging behaviours and mental health problems can also be seen in 
people with Down’s syndrome. 
Aside from dementia, mental health problems in people with Down’s 
syndrome are less common than others with intellectual disability (Cooper, 
2009a). Mental health problems can include obsessional features, attention 
deficit and hyperactivity disorder, aggressive behaviour, mood disorders or 
psychosis. Autism can be a co-morbidity in Down’s syndrome, with a 
frequency that may be as high as 7% (Kent et al, 1999). 
Dementia is very common in people with Down’s syndrome. Dementia in 
Down’s syndrome usually presents as an Alzheimer’s-type dementia and will 
be discussed in further detail in Section 1.5.  
1.5.5 Speech and language 
Children with Down’s syndrome have delayed speech and language 
development and speech and language therapy is recommended from an 
early age. Speech and language problems in people with Down’s syndrome 
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have been well described, and relate to both articulation difficulties and 
cognitive difficulties. Articulation difficulties are likely to be related to 
structural features of the tongue and palate (as people with Down’s 
syndrome often have a large tongue in comparison to their small oral cavity) 
as well as dyspraxia resulting in poor coordination of tongue and palate 
movements.  
Other difficulties include relative weaknesses in phonology, vocal imitation, 
mean length of utterance and expressive syntax (Pennington et al, 2003). 
Grammatical difficulties may be explained by a relative weakness in verbal 
short term memory (Naess et al, 2011), which will be described in further 
detail in Section 1.4.6. 
1.5.6 Cognitive profile 
It was previously thought that people with Down’s syndrome have a global 
cognitive impairment, with a proportional reduction in all cognitive skills when 
compared to those without intellectual disability. More recent research has 
proven otherwise, and it is now clear that in Down’s syndrome, as in many 
genetic syndromes associated with intellectual disability, the cognitive profile 
includes relative strengths and weaknesses.  
In people with Down’s syndrome, as in the general population, the pattern of 
cognitive skills develops and changes with age. Alongside this, historical 
changes in the education and welfare systems mean that we need to be 
cautious when comparing present day cognitive studies in children and 
adolescents to studies in those who are older adults. 
There is a large and growing body of research in the field, much of which 
focuses on verbal short term memory, which is a relative weakness in people 
with Down’s syndrome (Jarrold and Baddeley, 2001). More recently, research 
has also examined visual and visuo-spatial memory skills and executive 
functions.  
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It has been hypothesised that it may be the late-developing brain regions, 
including the prefrontal (Edgin, 2013), hippocampal and cerebellar (Nadel, 
2003) regions which may be more affected in people with Down’s syndrome.  
In reality, “cognitive functions” are often associated with multiple brain 
regions and pathways, and a number of areas of the brain may be associated 
with one specific cognitive skill. Therefore, it is important to remember that 
the use of neuroanatomical terminology (e.g. “prefrontal skills” or 
“hippocampal skills”) to define cognitive tasks has its limitations, as often 
multiple brain regions are involved in each specific cognitive task. Specific 
cognitive skills are also likely to be influenced by a number of different brain 
functions, such as sight, hearing, attention or concentration.  
It can be useful to consider the cognitive profile of people with Down’s 
syndrome in terms of specific cognitive strengths and deficits.  A full and 
detailed description of the cognitive profile of people with Down’s syndrome 
is beyond the scope of this thesis. I will therefore discuss areas of particular 
interest in relation to my research study. I have used a combination of 
original references and review articles when describing Down’s syndrome in 
section 1.5. In section 1.6, I will discuss dementia in Down’s syndrome in 
more detail. In this section, which relates more specifically to my research 
question, I have focussed on using original references.  
The cognitive profile of people with Down’s syndrome includes weaknesses 
in the prefrontal, hippocampal and cerebellar domains (Nadel, 2003), with 
disproportionally smaller brain volume in these areas (Gardiner et al, 2010). 
The prefrontal cortex plays an important role in executive function and 
working memory and the hippocampus is important for long term memory. In 
the remainder of this section, I will summarise the relevant literature on 
cognitive skills in people with Down’ syndrome. 
1.5.6.1 Executive function 
The prefrontal cortex is involved with executive function. This is a late-
developing region, which continues to undergo developmental change into 
early adulthood (Edgin, 2013). Executive function has been described as “a 
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set of interrelated control processes involved in the selection, initiation, 
execution and monitoring of cognition, emotion and behaviour, as well as 
aspects of motor and sensory functioning” (Roth et al, 2005). Executive 
function is a complex combination of cognitive skills including initiation, set 
shifting, response inhibition, working memory, planning and organising and 
emotional regulation. Impaired executive functioning is seen in people with 
Down’s syndrome, which may be related to the abnormal development of the 
prefrontal cortex in this population (Rowe et al, 2006). The cerebellum is also 
thought to play a role in executive function. 
Interestingly, Pennington et al found no significant differences on individual 
measures of executive function between 28 school aged individuals with 
Down’s syndrome (mean age 14.7 years) and 28 mental age matched 
controls (mean age 4.9 years) (Pennington et al, 2003). The measures used 
were CANTAB Stockings of Cambridge (a computerised version of the Tower 
of London task), NEPSY Verbal Fluency, NEPSY Design Fluency, the 
Stopping task, CANTAB Spatial Working Memory task and the Counting 
Span task. They demonstrated a correlation of 0.54 between hippocampal 
and prefrontal composite scores in the Down’s syndrome group, when 
controlling for chronological age, highlighting the fact that, although the two 
domains are related to different cognitive skills, there is some overlap 
between them.  
Further pilot work from the same research group, however, found that verbal 
prefrontal tasks might detect differences and it has been suggested that the 
modality in which information is recalled may moderate the results (Jarrold et 
al, 2008).  
In a later study, the same group found significant differences when 
comparing 55 individuals with Down’s syndrome (from a larger sample of 
people with Down’s syndrome aged 7-38 years old) to 36 mental age 
matched controls in computer-based tests of set shifting (CANTAB IED) and 
working memory and inhibitory control (Modified dots task, combined phase) 
(Edgin et al, 2010a). The CANTAB IED task and Modified dots task are 
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largely non-verbal tasks (ie. they do not require verbal responses), and this 
difference is therefore not explained by a verbal modality.  It is not clear why 
these tests showed a significant difference between individuals with Down’s 
syndrome and mental age matched controls, when no differences were found 
in the previous study. This may be due to differences in sample size, 
differences in the ages of participants or, perhaps because the prefrontal 
tests used in Edgin’s 2010 study were more sensitive. 
Studies have demonstrated specific deficits in working memory and set 
shifting in children and adults with Down’s syndrome. Lanfranchi et al 
demonstrated that 15 adolescents with Down’s syndrome performed at a 
significantly lower level when compared to 15 mental age matched typically 
developing children on tasks assessing set shifting, planning/problem-
solving, working memory and inhibition/perseveration but not on the tasks 
assessing verbal fluency (Lanfranchi et al, 2010).  
Rowe et al found that 26 adults with Down’s syndrome (mean age 33.35 
years) performed at a significantly lower level on a number of tests that 
assessed executive function compared to 26 age matched participants with 
intellectual disability who did not have Down’s syndrome (Rowe et al, 2006). 
After correcting for multiple comparisons, a significant group effect remained 
for the Weigl Colour-Form Sort Test (a test of set shifting), Attention 
Sustained (a test of attention) and Raven’s Coloured Progressive Matrices 
(used to assess non-verbal reasoning ability).  
1.5.6.1.1 Working memory  
Working memory refers to short term memory, where “information is actively 
held ‘online’ so that it may be manipulated and transformed in the service of 
planning and guiding cognition and behaviour” (Roth et al, 2005). I will 
therefore use the terms working memory and short term memory 
synonymously in this thesis.  
Baddeley proposed abandoning the concept of a single unitary short term 
memory in favour of a working memory model. His working memory model 
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included a central executive and two temporary storage systems: a 
phonological loop (related to verbal short term memory) and a visuo-spatial 
sketchpad (related to visuo-spatial short term memory) (Baddeley and Hitch, 
1974; Baddeley, 1986). The phonological loop processes verbal information 
using a process of rehearsing phonological sounds (words) and the visuo-
spatial sketchpad processes memories through visual imagery. This model 
was later revised to include an episodic buffer, which integrates information 
from the subsidiary systems and long term memory into a single episodic 
representation (Baddeley, 2000). It is thought that the central executive 
component of working memory relies on the prefrontal cortex (Edgin et al, 
2010b).  
There is a large body of research that has examined verbal short term 
memory in people with Down’s syndrome (Laws, 2002; Jarrold et al, 2002; 
Jarrold et al, 2008). In summary, this has shown that verbal short term 
memory in people with Down’s syndrome is a relative weakness and it has 
been hypothesised that deficits in verbal short term memory may lead to the 
comparatively weaker verbal abilities seen in people with Down’s syndrome, 
although this is an area that requires further research (Jarrold et al, 2008). 
Other studies have also looked at visuo-spatial working memory in people 
with Down’s syndrome. Lanfranchi et al found that there was a dual task 
deficit when assessing 45 children with Down’s syndrome and 45 verbal 
mental age matched children (Lanfranchi, 2012). They found impairments in 
the Down’s syndrome group in verbal tasks and further impairment in all 
dual-task (verbal and visuo-spatial working memory task) conditions.  
Visu-Petra et al administered 5 CANTAB visuo-spatial tasks to 25 children 
with Down’s syndrome and 25 mental age matched controls (Visu-Petra et al, 
2007). They did not find support for a visual versus spatial dissociation in 
recognition memory and concluded that performance impairment in the 
visuo-spatial domain parallels the increase in working memory.  
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1.5.6.2 Long Term Memory 
Long term memory has been described as memory for storage of material 
that is not kept active. It can be divided into implicit memory (non-conscious 
knowledge and learning) and explicit memory (consciously recollected 
memory for facts and events) (Jarrold, 2008). The hippocampus is important 
for explicit memory, and is involved in consolidating networks for long-term 
retrieval of information (Edgin et al, 2010b). Different theories propose 
different main functions of the hippocampus. In the Cognitive Map Theory, 
the hippocampus is thought to be specialised to process spatial information 
(O’Keefe and Nadel, 1978). However, the Relational Theory (Cohen and 
Eichenbaum, 1993) and Declarative Theory (Squire, 1986) suggest that the 
hippocampus has more general processing mechanisms and is important in 
the development of both spatial and semantic memory (Edgin et al, 2010b). 
A number of the studies examining explicit long term memory in people with 
Down’s syndrome have studied memory for verbal rather than visuo-spatial 
information (Jarrold et al, 2008).  
Carlesimo et al investigated long term memory in 15 people with Down’s 
syndrome (mean age 16.7 years) and compared them to 15 people with 
other intellectual disability (mean age 17.1 years) and 30 mental age 
matched children. They used tests of verbal and visuo-perceptual explicit 
memory and a verbal repetition priming task and found that people with 
Down’s syndrome performed the poorest in the tests for explicit memory and 
had a particular difficulty in organising verbal material (Carlesimo et al, 1996). 
In a study by Vicari et al, 15 participants with Down’s syndrome (mean age 
16 years, 5 months) were found to have typical learning of visuo-spatial 
sequences but impaired learning of visuo-object patterns compared against a 
mental age matched control group (Vicari et al, 2005). This was in contrast to 
participants with Williams syndrome (another genetic syndrome associated 
with intellectual disability and often studied in comparison to people with 
Down’s syndrome), who displayed a different profile.  This finding highlights 
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that visuo-object and visuo-spatial processes are likely to be mediated by 
different neural networks.  
As previously reported, a number of studies from the Down Syndrome 
Research Group, based in the USA (the group that published the Arizona 
Cognitive Test Battery), have examined cognition, including long term 
memory in people with Down’s syndrome (Pennington et al, 2003; Edgin et 
al, 2010a). Alongside findings on prefrontal skills, as reported above, 
Pennington et al identified poorer performance in participants with Down’s 
syndrome compared to mental age matched controls in all the hippocampal 
measures evaluated (NEPSY list learning, Morris water maze, CANTAB 
Pattern Recognition and CANTAB Paired Associates Learning (PAL)) 
(Pennington et al, 2003).  
In another study from the same research group, comparing adolescents and 
young adults with Down’s syndrome (n=27) or Williams Syndrome (n=28) 
and closely matched chronological age and IQ matched controls, different 
patterns of strengths and weaknesses in memory were identified, with verbal 
immediate memory (digit span) being most related to variation in IQ and 
spatial associative memory (CANTAB PAL) being related to adaptive 
behaviour in the Down’s syndrome group (Edgin et al, 2010b).  
In a separate study, a significant difference was found when the number of 
CANTAB PAL first trials correct (a measure of spatial associative memory) 
was compared between a group with Down’s syndrome (n=55) and a mental 
age matched control group (n=36). No significant difference was seen in the 
Computer-generated arena task (a measure of spatial memory) based on the 
Morris Water Maze (Edgin et al, 2010a). 
1.5.6.3 Cerebellar functions 
The cerebellum is well known for its role in motor functions, including 
coordination and balance. However, in recent years, it has become 
acknowledged that the cerebellum also has a role in cognition. This is yet to 
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be fully understood, but it is hypothesised that the cerebellum’s role in mental 
functions parallels its role in motor functions, forming an internal model 
through repeated performance and feedback (Buckner, 2013).  
A recent systematic review of PET and fMRI studies and cognition has 
identified some of the main cognitive functions of the cerebellum. These 
include executive function, working memory, emotion, language and music 
and timing (Keren-Happuch et al, 2012). 
People with Down’s syndrome have smaller cerebellar volumes (Pinter et al, 
2001). This may be related to the fine movement and gait problems that are 
also often seen in people with Down’s syndrome.  
A study in human foetuses with Down’s syndrome at 17-21 weeks gestation 
found that the cerebellum had an immature pattern, reduced volume and 
fewer cells in all cerebellar layers. The authors suggest that in foetuses, the 
reduction in cerebellar cells results from a reduction in cell proliferation rather 
than increased cell death (Guidi et al, 2011). 
Interestingly, studies in mice have shown that the cerebellar morphology can 
be normalised by using SAG, an agonist of the Sonic Hedgehog pathway (a  
pathway that is known to have a role in early development),  administered at 
birth. Although this normalises cerebellar morphology and restores the ability 
to learn a spatial navigation task (likely to be mediated by the hippocampus) 
(Das et al, 2013), it has not been shown to restore cerebellum dependant 
motor learning deficits (Gutierrez-Castellanos et al, 2013). 
There is a large body of research on movement in people with Down’s 
syndrome, although the research specifically on cerebellar function itself is 
limited. People with Down’s syndrome have longer reaction times, movement 
times and greater movement errors in single limb, single target movements 
when compared to typically developing controls. These are thought to be 
related to both central as well as peripheral processes. (Lawrence et al, 
2013). 
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Research on cerebellar cognitive functions in people with Down’s syndrome 
is very limited. In Edgin’s recent study, a significant difference in cerebellar 
tasks between the Down’s syndrome group and mental age matched controls 
was seen in one of the three cerebellar tasks administered (participants with 
Down’s syndrome had a longer mean latency in in the tabletop finger 
sequencing task, but there was no significant difference between the two 
groups in CANTAB SRT or NEPSY visuomotor precision) (Edgin et al, 
2010a).  
There is a need for a further understanding of the cerebellum’s role in 
cognition. Following this, further studies are then required to examine 
cerebellar cognitive skills in people with Down’s syndrome.  
1.5.6.4 Cognitive profile over time 
Patterson et al have recently reviewed the longitudinal studies looking at 
cognitive development across childhood in Down’s syndrome (Patterson et 
al, 2013). They found that all 6 studies that measured general IQ reported a 
decline in IQ over time. Of the 7 studies that measured specific cognitive 
domains, all 7 studied language and memory and 4 studies assessed visuo-
spatial skills. There was an increase in most of the test raw scores over time, 
and an increase in age-equivalent scores, although this was substantially 
slower than the rate of increase in chronological age of participants. Tests 
assessing receptive language and word recognition were more likely to 
improve than those testing phonological skill and short term memory. The 
authors concluded that cognitive trajectories in children and adolescents with 
Down’s syndrome cannot be clearly defined using current published data. 
I have not detailed all the studies included in this review, as they review 
studies in children and my research question relates to older adults. 
However, one of the studies that was included in the review paper has 
published further data on participants aged up to 45 years (data up until age 
21 was included in the review). This study examined cognitive function in a 
community sample of people with Down’s syndrome and found that there 
29 
were no statistically significant differences in cognitive functions (including 
intelligence, language, reading, arithmetic and daily living skills) from age 21 
and/or 30 compared to the same individuals at age 35 (Carr J, 2003). In a 
further follow up of this sample, apart from two participants with a diagnosis 
of dementia, mean IQs (verbal and non-verbal) changed very little from age 
21 to age 45. However, scores on memory tests (Oliver and Crayton’s 
dementia battery and Rivermead Behavioural Memory Test for Children) had 
declined, in some cases significantly. The author suggests that this may 
indicate that other members of the cohort may be showing early signs of 
dementia (Carr J, 2012). 
Dementia and subsequent decline in cognitive functions most commonly 
presents when people with Down’s syndrome are in their 50s, but can 
present earlier in some individuals. Dementia will be discussed later on in this 
chapter. 
An MRI study of adults with Down’s syndrome found that although cerebellar 
volumes were disproportionately small in adults with Down’s syndrome 
compared to controls, they did not reduce significantly with age any more 
than the control group. The authors concluded that cerebellar volume did not 
appear to be responsible for the age related decline in fine motor control 
seen in people with Down’s syndrome (Aylward et al, 1997). 
1.5.6.5 Summary 
There has been extensive research looking at the cognitive profile of people 
with Down’s syndrome. The research indicates that people with Down’s 
syndrome have relative weaknesses in some aspects of executive function 
and memory, in particular, verbal short term memory. There is some 
evidence that they may have impairments in cerebellar cognitive function, but 
there is a need for further research in this area.  
In childhood, IQ has been shown to decline over time. In younger adulthood, 
it may be that IQ remains fairly stable, until some people present with the 
cognitive decline associated with dementia in Down’s syndrome. 
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Although cognition in Down’s syndrome is a large and rapidly growing 
research field, it is often difficult to compare studies, as many studies use 
different cognitive tests in different populations and with different age groups. 
Some studies use mental age matched controls, others use chronological 
age matched controls and others use controls from the intellectual disability 
population (including controls with no genetic diagnosis and controls with 
other genetic syndromes, such as Williams syndrome). These have their 
individual advantages and disadvantages: studies which use mental age 
matched controls use a control group of comparable mental age but controls 
are often at a much younger chronological age and have therefore had less 
life experience to allow for the learning or development of certain skills, such 
as motor or computer based skills. The reverse is true for studies that use 
chronological age matched controls and for this reason, chronological age 
matched controls are less commonly used in more recent studies. Studies 
which use controls from the intellectual disability population may be limited by 
a number of factors, including the heterogeneity of the population and the 
specific cognitive differences known to be found in people with some genetic 
syndromes. 
Studies that use cognitive assessment batteries are likely to require multiple 
analyses and there is a danger of generating type I errors (ie. false positive 
results) and/or that negative findings are not reported. Very few of the studies 
report a power calculation and it is therefore difficult to determine whether 
analyses may be likely to generate any type II errors (ie. false negative 
results). While it is important to bear these limitations in mind when 
considering the research in this area, it is also important to acknowledge the 
contribution that research on cognition in people with Down’s syndrome has 
made to our understanding of cognition and cognitive deficits in people with 
Down’s syndrome, in people with intellectual disability and in the general 
population. 
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1.6 Dementia in Down’s syndrome 
Dementia is characterised by a decline from baseline functioning in memory 
and other cognitive and daily living skills. In ICD-10, a decline in emotional 
control, motivation or social behaviour is also required for a diagnosis (World 
Health Organisation, 1992). 
The definition of dementia is given in the international classification systems, 
ICD-10 (World Health Organisation, 1992) and DSM-IV (American 
Psychiatric Association, 2000). In order to make a diagnosis, both 
classification systems require development of a decline in memory and other 
cognitive functions. DC-LD is a diagnostic classification system based on 
ICD-10, and designed for use in adults with moderate to profound intellectual 
disability (Royal College of Psychiatrists, 2001). It emphasizes the 
importance of a change from a baseline level of functioning  
In DSM 5, dementia is found in the category of Major Neurocognitive 
Disorder (American Psychiatric Association, 2013). One of the main 
differences between DSM 5 compared to DSM-IV and ICD-10 is that 
although a decline in cognitive skills is required for a diagnosis, this does not 
necessarily need to include a decline in learning and memory. Other 
cognitive skills that may be seen to decline in the DSM 5 diagnosis include 
complex attention, executive function, language, perceptual-motor and social 
cognition. It also specifies that diagnosis should be based on informant report 
and an impairment in cognitive performance, ideally measured through 
standardised neuropsychological testing.  This highlights the importance of 
assessing a range of cognitive skills, including, but not limited to memory, 
and using neuropsychological testing as well as informant report when 
assessing for a diagnosis of dementia. It remains to be seen how the revised 
editions of ICD (due to be revised in 2015) and the recently revised DSM 5 
diagnostic criteria will affect the diagnosis of dementia in people with 
intellectual disabilities. 
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Alzheimer’s disease is a type of dementia which can present insidiously with 
a decline in memory, with subsequent gradual deterioration of brain 
functions, including decline in other cognitive skills. It is the most common 
type of dementia both in the general population and amongst people with 
intellectual disability.  
Pathological features of Alzheimer’s disease include amyloid plaques and 
neurofibrillary tangles in the brain The amyloid cascade hypothesis suggests 
that amyloid deposits are causative of Alzheimer’s pathology, leading to 
neurofibrillary tangles, vascular damage, neuronal cell loss and dementia 
(Hardy and Higgins, 1992), although this hypothesis continues to be revised 
and challenged (Ballard et al, 2011). 
Mutations in genes related to the production of amyloid, including Presenilin 
1 and Presenilin 2 and Amyloid Precursor Protein (APP) are associated with 
early onset, autosomal Alzheimer’s disease (Hardy, 1997). Genome-wide 
association studies (GWAS) have suggested several new genes associated 
with Alzheimer’s disease (Harold et al, 2009).  
Other types of dementia include vascular dementia, Lewy-body dementia, 
Fronto-temporal dementias as well as dementias due to other conditions 
such as dementia in HIV or dementia in Parkinson’s disease. In the general 
population, mixed patterns of dementia (for example, mixed Alzheimer’s 
disease and vascular dementia) are common.  
Over the past few decades, with improvements in the life expectancy of 
people with Down’s syndrome, it has become more evident that one of the 
behavioural phenotypes of Down’s syndrome is the increased risk of 
developing dementia of Alzheimer’s type (DAT). 
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1.6.1 Neuropathology  
1.6.1.1 Genetics 
At present, the most accepted hypothesis as to why people with Down’s 
syndrome are at greater risk of developing dementia of Alzheimer’s type is 
that it is related to the Amyloid Precursor Protein (APP) gene. Amyloid 
Precursor Protein (APP) is one of the proteins associated with the production 
of amyloid. The gene that codes for APP is located on chromosome 21 and is 
therefore triplicated in people with Down’s syndrome, resulting in an 
overexpression of APP. It has been shown that the number of trinucleotide 
repeat alleles in APP can influence the age of onset of dementia in Down’s 
syndrome (Margallo-Lana et al, 2004) 
Several other genes on chromosome 21 are also may potentially be related 
to the development of dementia of Alzheimer’s type in people with Down’s 
syndrome. This may include β-site APP cleaving enzyme-2 (BACE-2), which 
has been shown to affect age of onset of dementia (Mok et al, 2014) and 
DYRK1A (Park et al, 2009)   
There has also recently been increased interest in other genes that may play 
a cumulative role in predisposing to dementia, both in the general population 
and in people with Down’s syndrome. The variant of gene apolipoprotein E 
(APO-E) allele 4 is known to be associated with an increased risk of 
developing Alzheimer’s disease in the general population (Ballard et al, 
2011). APO-E has also been shown to influence the development and 
progression of dementia of Alzheimer’s type in people with Down syndrome 
(Prasher et al, 2008).  
A recent study has identified associations with the age of onset of 
Alzheimer’s disease in people with Down’s syndrome with PICALM and the 
APO-E loci (Jones et al, 2013). Further genome-wide association studies 
(GWAS) are likely to increase our understanding of genetic factors in 
dementia in people with Down’s syndrome. 
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1.6.1.2 Brain Pathology 
In older adults with Down’s syndrome without dementia, changes in medial 
temporal lobe volume have been shown to occur with age and to be related 
to memory (Krausky et al, 2002). This can make it difficult to determine 
dementia in people with Down’s syndrome through brain scans, as brain 
atrophy is a feature of Alzheimer’s disease and early changes may be seen 
in the medial temporal lobes (Tartaglia et al, 2011). 
Potential dementia indicators (using the carer rated DLD questionnaire) in 
people with Down’s syndrome have been shown to be correlated with both 
structural and functional brain changes (including the combination of 
decreased grey matter volume and increased cerebral glucose metabolic rate 
in parts of the brain, including the parahippocampus/hippocampus and frontal 
lobe) (Haier et al, 2008). 
Alzheimer’s pathology is thought to be present in the brains of virtually all 
people with Down’s syndrome aged 40 and over (Head & Lott, 2004), 
although not all adults with Down’s syndrome develop the symptoms of 
dementia. Previous research has shown that a diagnosis of dementia in 
people with Down’s syndrome is more closely related to the density of 
neurofibrillary tangles rather than the density of amyloid plaques (Margallo-
Lana et al, 2007). 
1.6.1.3 Other Factors 
There are a number of factors that may play a role in influencing the 
presentation of dementia in people with intellectual disability. Comorbidities, 
such as epilepsy, which is more prevalent in people with intellectual disability 
(McGrother et al, 2006), may influence the presentation. Also, people with 
intellectual disabilities may have a lower cognitive reserve due to lower 
baseline cognitive function. This may lead to earlier development of 
symptoms during the course of dementia, as low cognitive reserve is rapidly 
overcome by the disease (Strydom and Sinai, 2014).  
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Important modifiable risk factors for Alzheimer’s disease can include factors 
such as obesity, smoking, physical activity and alcohol intake (Ballard et al, 
2011). Some of these risk factors may be more common in people with 
Down’s syndrome, including obesity (de Winter et al, 2012) which may be 
related to genetic factors as well as reduced exercise, poorer awareness of 
healthy eating and certain medications.  
The specific protective factors in those people with Down’s syndrome who do 
not develop the clinical features of dementia are still not fully understood, and 
risk is likely to be related to a combination of factors, including genetic and 
environmental factors. 
Improved understanding of the neurobiology of Down’s syndrome is now 
leading to consideration of potential treatment options for improving cognitive 
functioning or modifying the dementia process in people with Down’s 
syndrome. Several successful mouse model studies have led to several trials 
in humans (Costa and Scott-McKean, 2013), including a recent trial of 
memantine in people with Down’s syndrome (Hanney et al, 2012).   
1.6.2 Epidemiology  
Dementia in Down’s syndrome presents at a younger age and at a higher 
rate than the general population (see Sinai et al, 2014 for a review). The 
prevalence of dementia in adults with Down’s syndrome aged between 40 
and 49 has been found to range from approximately 6%  to approximately 
10% (Tyrrell et al, 2001; Holland et al, 1998). Between 50 and 59 years of 
age, 30 - 40% of people with Down’s syndrome have been estimated to have 
a diagnosis of dementia (Tyrrell et al, 2001; Holland et al, 1998), and 
estimates in those aged 60 and older range from 26% to 77% (Coppus et al, 
2006; Visser et al, 1997). Prevalence rates of dementia in people with 
Down’s syndrome are considerably higher than the prevalence of Alzheimer’s 
disease in people with intellectual disability aged 60 and over who do not 
have Down’s syndrome, which has been estimated at around 8.6% (Strydom 
et al, 2007). Incidence of dementia in people with Down’s syndrome has 
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been shown to increase with age, and incidence in those aged 60 and older 
has been found to be 13.3 per 100 person years (Coppus et al, 2006). 
Unlike Alzheimer’s disease in the general population, in which female gender 
is associated with an increased risk of Alzheimer’s disease (Launer et al, 
1999), risk of dementia in people with Down’s syndrome has not been found 
to be associated with gender. However, the age at onset of dementia in 
women with Down’s syndrome has been shown to be correlated with the age 
of onset of menopause, with earlier onset of dementia associated with earlier 
menopause (Cosgrave et al, 1999).  
One follow up study in an institutionalised sample of people with Down’s 
syndrome found that the median age of onset of dementia was 55.5 years, 
with a mean age at death of 59.3 years (Margallo-Lana et al., 2007). A recent 
survival analysis of a community sample found that survival from diagnosis of 
dementia to death was approximately 5 years (Mockryz C et al, personal 
communication), which is comparable to survival rates from time of diagnosis 
in the general population, although age at diagnosis in the Down’s syndrome 
population is much lower than in the general population.  
1.6.3 Cognitive profile  
Like the general population, memory changes are an important symptom in 
dementia in people with Down’s syndrome. Although there are differences in 
the clinical presentation of dementia in people with Down’s syndrome, it is 
generally accepted that the type of dementia that is commonly seen in people 
with Down’s syndrome is dementia of Alzheimer’s type.  
Older adults with Down’s syndrome have been shown to perform more poorly 
on cognitive tests, particularly those requiring planning and attention, when 
compared to younger adults with Down’s syndrome and both older and 
younger adults with non-Down’s syndrome intellectual disability (Das et al, 
1995). 
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Adams and Oliver studied 30 adults with Down’s syndrome at three time 
points over 16 months. Ten participants showed cognitive deterioration 
during this time. The group with cognitive deterioration showed decreases on 
measures of executive function and significant changes in behaviour during 
the course of the study, which were not just due to memory decline. The 
study showed that in the stages before a diagnosis of dementia, adults with 
Down’s syndrome have an increased frequency of behavioural excesses and 
deficits (Adams and Oliver, 2010). 
Although forgetfulness and confusion are common early symptoms, frontal 
lobe related features, including diminished initiative and social withdrawal 
also present early in dementia in people with Down’s syndrome (Deb et al, 
2007). In this qualitative study, Deb et al also noted a general slowness, 
including slowness in activities and speech. 
These two studies draw attention to early frontal lobe related features in 
dementia in people with Down’s syndrome and go some way to supporting 
Ball et al’s finding that adults with Down’s syndrome may meet the criteria for 
a dementia of frontal type before they progress to meeting the criteria for 
Alzheimer’s disease (Ball et al, 2006a). When a group of older adults were 
assessed using six executive function tests and six memory measures, Ball 
et al found that the group with dementia of Alzheimer’s type (DAT) (n=25) 
showed impaired performance on all measures compared to the non-DAT 
group (n=78) (Ball et al, 2008). In a further analysis on the non-DAT group, 
they found that disinhibited behaviours were more commonly reported by 
carers than apathy or executive dysfunction and proposed that the biological 
basis for this may be through the serotonergically mediated orbito-frontal 
circuit (Ball et al, 2010).  
Cognitive functions have been shown to decline sequentially, with different 
cognitive functions being affected at different stages of the dementia. Those 
with “questionable” dementia, as well as having memory loss, have 
demonstrated declines in block design and coding subsets, those at an 
“early” stage show the previous declines, as well as declines in object 
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assembly, picture completion (visuo-spatial organisation), arithmetic and 
comprehension (working memory) and those in the “middle” stage of 
dementia show the previous declines as well as declines in information, 
vocabulary (sematic memory) and digit span (short term memory) (Devenny 
et al, 2000).  
In a longitudinal study in the USA, Krinsky-McHale et al (2002) showed that 
14 participants with early stage dementia of Alzheimer’s type and Down’s 
syndrome showed severely diminished verbal long term storage and retrieval 
processing abilities compared to the group of 71 participants without a 
diagnosis of dementia. 
1.6.4 Other clinical features  
When behavioural and emotional changes in people with Down’s syndrome 
and dementia were compared with a group of people with Alzheimer’s 
disease from the general population, the group with Down’s syndrome were 
more physically active, although they had fewer behavioural problems and 
delusions (Temple and Konstantareas, 2005).   
The later stages of dementia in Down’s syndrome are often associated with 
mobility issues and falls, and myoclonic jerks and epilepsy. The frequency of 
myoclonic jerks and epilepsy in Down’s syndrome and dementia is much 
higher than in the general population. A recent longitudinal study reported 
epilepsy in 74% of participants with Down’s syndrome and dementia and 
noted that the onset of epilepsy was often within the same time period as 
dementia decline (McCarron et al, 2014).  
End stage dementia in people with Down’s syndrome can present with similar 
symptoms to end stage dementia in the general population and can include 
severe memory impairment, changes in personality and affect as well as 
incontinence, immobility and a complete loss of self care skills (Prasher, 
1995). 
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1.6.5 Summary 
Dementia in older adults with Down’s syndrome is common, although 
estimates of prevalence rates vary. Dementia typically presents at around 
age 55, which is much younger than dementia in the general population. 
Although there are differences in the clinical presentation of dementia in 
people with Down’s syndrome, including early presentation of frontal lobe 
related features and an increased rate of epilepsy, it is generally accepted 
that the type of dementia that is commonly seen in people with Down’s 
syndrome is dementia of Alzheimer’s type.  
1.7 Measuring cognitive deficits in people with Down’s 
syndrome 
There are several assessment tools that can be used for assessing cognitive 
skills and/or dementia in people with intellectual disability, as demonstrated 
by the extensive literature in the area.  Most tests require assessments at 
repeated intervals in order to assess change from baseline functioning. There 
is some overlap between those tools that assess for dementia and those that 
assess cognitive function. 
Measurement of cognitive deficits in people with Down’s syndrome can be 
challenging. Several factors can influence performance, including sensory 
deficits, particularly hearing and visual problems. Attention, concentration 
and verbal abilities can also affect performance. Alongside verbal abilities, 
the language of the participant and language that the tests are administered 
in will affect performance and it is important to note that most of the tests are 
designed by and for use in Western countries, where English is the first 
language. Alongside this, differences in American English and British English 
may require slight alterations in instruction manuals.  
As previously mentioned, a participant’s educational and past social history 
may affect performance, particularly when considering the differences in 
health and education systems over the past 50 years and when comparing 
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opportunities given to those brought up in a family environment compared to 
those brought up in an institution. Other factors that may influence 
assessment are the environment the assessment is conducted in – including 
location, familiarity, any distractions and who the participant is supported by. 
A particular issue for cognitive assessments in people with Down’s syndrome 
is their relatively poor verbal abilities, which may act as a confounder in tests 
that require verbal responses. 
A recent systematic review has compiled a list of assessment instruments for 
dementia in Down’s syndrome (Zeilinger et al, 2013). The authors identified 
114 different instruments, including 79 instruments involving the person with 
Down’s syndrome and 35 informant rated assessments. They also identified 
4 test batteries. They highlighted that despite the variety of tools, there is 
currently no consensus on how best to assess dementia in this population 
and suggested that a consensus approach or instrument would be valuable 
for research and clinical practice. 
See Table 1.1 for some of the common screening and assessment tools that 
can be used when assessing dementia in people with intellectual disability. 
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Table 1.1 – Some tools used to assess dementia in people with intellectual 
disability – adapted from British Psychological Society and Royal College of 
Psychiatrists, 2009 (Strydom and Sinai, 2014) 
Informant rated tools 
Dementia Questionnaire for people with Learning Disabilities, DLD 
(Evenhuis et al, 2007) 
Dementia Screening Questionnaire for Individuals with Intellectual 
Disabilities, DSQUIID (Deb et al, 2007b) 
Adaptive Behaviour Dementia Questionnaire, ABDQ (Prasher et al, 
2004)  
CAMDEX-DS informant interview (Ball et al, 2006b) 
Assessments of daily living skills and functioning 
Assessment of Motor and Process Skills (AMPS) (Fisher, 2006) 
AAMD Adapted Behaviour Scales (ABS) (Nihira et al, 1974) 
Adaptive Behaviour Assessment System-II (ABAS-II) (Harrison and 
Oakland, 2003) 
Vineland Adaptive Behaviour Scales: Second edition (Sparrow et al, 
2007) 
Test Batteries 
CAMCOG-DS (Ball et al. 2006b) 
Neuropsychological Assessment of Dementia in Adults with 
Intellectual Disabilities (NAID) (Crayton et al, 1998) 
Severe Impairment Battery (Saxton et al, 1993) 
Test Battery for Dementia (Burt and Aylward, 2000) 
42 
1.7.1 The Arizona Cognitive Test Battery (ACTB) 
The Arizona Cognitive Test Battery (ACTB) has been developed in the USA 
to assess cognitive function in detail in people with Down’s syndrome. It 
assesses three specific brain areas that are known to be associated with 
cognitive difficulties in people with Down’s syndrome; the prefrontal, 
hippocampal and cerebellar areas (Edgin et al, 2010a). It has been validated 
for use in both lab and home environments and is designed to assess non-
verbal responses, in order to reduce the fact that poor verbal ability may 
confound results. In an attempt to overcome potentially high floor levels in 
this population, several of the tasks include measurements of errors as well 
as measures of success.  
It has been validated amongst children and adults with Down’s syndrome, up 
until the age of 35. It has not been validated in older adults with Down’s 
syndrome, and it is not known if the battery would be of value in assessing 
for dementia and whether it can distinguish between older adults with and 
without dementia of Alzheimer’s type.  
Validation of this test battery in older adults with Down’s syndrome is 
important, given the high risk of dementia in this group. Furthermore, the 
psychometric properties and floor effects of the ACTB need to be confirmed 
in an older population as it may differ compared to younger adults due to 
known changes in cognitive skills, as described previously, as well as 
additional morbidity such as vision and hearing problems.  
With the recent trials for cognitive enhancers for those with intellectual 
disability associated with specific syndromes (Kuehn, 2011) and advances in 
pharmacological treatments for Alzheimer’s disease, there is an increased 
need to obtain acceptable, validated and standardised neuropsychological 
measures of cognitive function in people with Down’s syndrome. 
Neuropsychological measures of cognitive function can also help clarify a 
diagnosis of dementia, and are more likely to be used in the future, both 
clinically and in research, as the emphasis in the diagnosis of dementia 
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moves away from a condition of memory loss to that of a neurocognitive 
disorder, which may feature a variety of cognitive deficits.  
It has been proposed that the ACTB could be used to measure outcomes in 
cognitive and dementia treatment trials in this population. It is hoped that this 
will help to target management and evaluate treatment efficacy more 
specifically.  
A further understanding of dementia in people with Down’s syndrome may, in 
turn, lead to a better understanding of dementia in the general population, 
and may go on to improve management of the increasing population that is 
affected by this disease. 
1.8 Summary  
The life expectancy of people with Down’s syndrome is increasing, with more 
people now living into their 60s and 70s. Over recent years, it has become 
more evident that people with Down’s syndrome are at increased risk of 
dementia. Alongside this, people with Down’s syndrome have specific 
cognitive deficits, including relative weaknesses in some aspects of executive 
function and verbal memory. The Arizona Cognitive Test Battery (ACTB) has 
been developed to assess prefrontal, hippocampal and cerebellar cognitive 
deficits in people with Down’s syndrome. It has been proposed that the ACTB 
could be used to measure outcomes in cognitive enhancer and dementia 
treatment trials in this population. It has not yet been validated in older adults 
with Down’s syndrome. 
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Chapter 2. Methods 
2.1 Overview 
In this chapter, I will first describe the aims of the study. I will then discuss 
specific ethical issues regarding capacity and consent relating to this study 
before describing the sample and setting of the study. Following this, I will 
detail the study procedures and the cognitive tasks used in this study. I will 
end by describing my analysis plan. 
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2.2 Aim 
To assess the use of the ACTB in older adults with Down’s syndrome and 
establish its validity in identifying the changes associated with dementia. 
2.3 Hypotheses 
2.3.1 Primary Hypothesis 
The ACTB is able to detect differences between people with Down’s 
syndrome who have early stage dementia and those who do not have 
dementia. 
2.3.2 Secondary Hypotheses 
 There are specific differences in the neuropsychological profiles of 
people with Down’s syndrome who have dementia and those who do 
not have dementia. These include differences in:  
o Prefrontal 
o Hippocampal 
o Cerebellar areas 
 
 The ACTB is a valid test battery for use in older adults with Down’s 
syndrome. 
o It has acceptable floor and ceiling effects (i.e. similar to table 
top tests) 
o It has good concurrent validity when compared to traditional 
table top tests tapping into the same or similar brain functions 
o It has good concurrent validity when compared to informant 
ratings tapping into the same or similar brain functions  
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2.4 Ethics 
The study was approved by the North Wales – West Research Ethics 
Committee. NHS Research and Development and local NHS site 
permissions were also granted.  
The assessment battery and carer rated questionnaires represented a 
compromise between the desire, on the one hand, to obtain as much useful 
and relevant information as possible to answer the research question and on 
the other, to avoid long and tiresome assessments for the participant and 
their carers or relatives.  
At the request of the Research Ethics Committee, if a participant who had not 
been diagnosed with dementia by their care team presented with symptoms 
suggestive of dementia on the cognitive assessment, the care team was 
informed, in order to take the appropriate action.  
2.4.1 Capacity and Consent 
This study included participants who lacked capacity. I believed that it was 
important that people who lacked capacity were included in this study. This 
ensured that the data collected was relevant and generalisable to this 
population. It also allowed people with Down’s syndrome who may lack 
capacity to be included in research that may lead to improvements for them 
and others with Down’s syndrome and dementia.  
The study was conducted in accordance with the Mental Capacity Act 
(Department for Constitutional Affairs, 2005). The Mental Capacity Act has 
clear specifications about research with participants who may lack capacity. 
This includes identifying a consultee in cases where participants lack 
capacity to consent. It also stipulates that the research must be connected to 
the impairment that causes the lack of capacity and that the research would 
not be as effective if only those with capacity to consent were to participate. 
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In this study, both Down’s syndrome and/or dementia may result in lack of 
capacity to consent to the study. 
In order to aid understanding, the study information sheet and consent forms 
were developed in consultation with an accessible information officer (RL) 
and designed to be as accessible as possible for people with intellectual 
disabilities.  
In cases where a participant lacked capacity to consent, the decision was 
discussed with the participant as well as with a consultee. A personal 
consultee was approached in the first instance if possible or practical. If there 
was no personal consultee available, I identified a suitable nominated 
consultee, who was not involved in the study, as per the Mental Capacity Act. 
This was often a paid carer, or manager of the home or day centre. 
The consultee was given information about the role of a consultee in 
research, as well as an information sheet about the research and given the 
opportunity to ask questions.  
Participants (or their consultee, if the participant lacked capacity) could ask to 
withdraw at any time. The assessment was stopped if the participant, 
consultee, research or care team identified consistent signs that the 
participant was no longer happy to continue in the study.  
2.5 Setting 
The study was conducted in the Greater London area and surrounding 
counties. This is an area with a diverse population, including a large range of 
ethnic and socio-economic backgrounds, as well as having a variety of 
different types of accommodation for people with intellectual disabilities.  
There are a number of different services that support people with intellectual 
disabilities, including people with Down’s syndrome, living in London. These 
include community intellectual disability services, which are often integrated 
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health and social services teams, and specialised inpatient services. These 
services were approached and invited to nominate participants.  
2.6 Sample 
Participants were resident in the Greater London area or surrounding 
counties. 
Health professionals of community intellectual disability teams and one 
specialist inpatient service were asked to approach service users with 
Down’s syndrome. Several intellectual disability teams had a local database 
of people with Down’s syndrome who they support.  
Once participants were identified, the intellectual disability teams invited 
potential participants to join the study. An information sheet, with contact 
details for how to join the study was given to or posted to participants and 
their carers. The referring team passed on details of potential participants 
who agreed to find out more about the study to the research team.  
As recruitment through these channels was slow, I also approached local 
care homes or day centres to recruit participants.    
If the participant or their consultee agreed to participate in the study, I liaised 
with service users and their caregivers and arranged a time for the 
assessment. Assessments were conducted at a convenient place for 
participants; this was often at their home, a relative’s home or their day 
centre.  
2.6.1 Sample size calculation 
The sample size was calculated in consultation with a statistician (KR) using 
Sample Size Tables for Clinical Studies software (Machin et al, 2009).  The 
calculation assumed that CANTAB PAL first trial memory score is normally 
distributed with a standard deviation of 6.01 (based on previous research, 
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Edgin et al, 2010a). To detect an effect size of 0.74, at 80% power and with a 
5% overall significance level, it was calculated that a total of 60 participants 
(30 participants in each group) (68 if adjusted for a 10% dropout) would be 
required.  
2.7 Exclusion and inclusion criteria  
I used broad inclusion criteria in order to provide as generalisable a sample 
as possible and to maximise the sample size. 
2.7.1 Inclusion criteria 
- Men or women with a clinical diagnosis of Down’s syndrome  
- Aged 45 or over 
I included people on psychotropic medication, including those on 
cholinesterase inhibitors or memantine.  
Participants were required to be able to understand simple verbal commands 
and attempt simple puzzles and games.  
2.7.2 Exclusion criteria 
- Active medical problems, including untreated thyroid problems or 
epilepsy. (Participants with stable and treated medical problems were 
included.) 
- Active psychosis or affective disorder (Participants with stable and 
treated mental health problems were included.) 
- Previous CVA (Cerebrovascular Accident) or significant head injury  
 
Participants with sensory impairments that did not prevent them from being 
able to participate in the tasks were included. Participants with sensory 
impairments that prevented them from being able to participate in the tasks 
were not included.
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2.8 Study procedures 
After obtaining consent from the participant or their consultee, the individual 
was entered into the study.  
I met with participants and collected the data in one session if possible. 
However I took a flexible approach to this and at times data were collected 
over two or three sessions. Participants were offered a break half way 
through the assessment, or more as required. At the end of the assessment, 
participants were given a choice of a small gift (such as a sticker book, a 
colouring book or a CD) or a £10 gift voucher.  
Relatives or carers were asked to be present during the meeting and were 
asked to complete informant questionnaires while the participant completed 
the cognitive tests. On most occasions, this person was also the consultee. 
Where relevant, they were reminded not to guide the participant in 
completing the tests, but at times carers were able to offer helpful 
suggestions on how to engage participants or how to best communicate the 
instructions to participants.  
The data collection form was completed from verbal information given by the 
participant or informant in the first instance. Where applicable, specific 
variables were then cross-checked with the participant’s care team and/or 
medical records. 
A summary of findings was sent to the participant, the participant’s General 
Practitioner (GP) and their community intellectual disability team, where 
relevant, after the assessment. 
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2.8.1 Feasibility and pilot study  
An assessment manual was developed by adapting the ACTB manual 
(Edgin, 2012) and selected clinical table top assessments. Table top 
assessments were selected by identifying tests that assessed pre-frontal, 
hippocampal and cerebellar functions and were used either in research or 
clinically. Consideration was also given to the feasibility of the task. As very 
little is currently understood on cerebellar cognitive functions, and there are 
no widely used tests which specifically assess cognitive cerebellar function, 
motor cerebellar tests were used to assess cerebellar function. 
Where appropriate, I amended the wording of some of the assessments from 
American English and to more simple English. For example, in the CANTAB 
IED, when asking participants to identify the rule, I amended the term 
“correct” to “right”.  
The assessment was subsequently piloted on the first 3 participants. 
Following this, an additional teaching task, the CANTAB MOT task, was 
added to the computer tasks. 
2.8.2 Revision of study procedures 
A further revision was made half way through recruitment, where the virtual 
computer generated Arena task was taken out of the assessment battery. 
This was due to inaccuracies in screen resolution, leading to poorly 
identifiable visual cues that were essential for validity of the task.  
Half way through recruitment, the order of the tasks was counter-balanced, to 
reduce the potential effect of task position on performance.  
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2.8.3 Measures 
The Arizona Cognitive Test Battery (ACTB) (Edgin et al, 2010a) is a battery 
of cognitive tasks, designed to assess cognitive function in people with 
Down’s syndrome. It includes tasks from the CANTAB as well as a few 
additional tasks. It has been developed by the Down Syndrome Research 
Group, Department of Psychology, University of Arizona.  
The ACTB has been validated for use in children and adults with Down’s 
syndrome, until the age of 35. It assesses cognitive functioning in three 
domains: prefrontal, hippocampal and cerebellar areas. Tests that assess 
prefrontal functioning are the Modified dots task (which assesses inhibitory 
control and working memory) and CANTAB Intra-Extra Dimensional Set Shift 
(set shifting). Hippocampal function is assessed by the CANTAB Paired 
Associates Learning task (spatial associative memory) and Virtual computer 
generated Arena (spatial memory). Cerebellar functions are assessed using 
the Finger sequencing task (motor sequencing), NEPSY visuomotor 
precision (visuo-motor tracking and hand-eye coordination) and the CANTAB 
Simple Reaction Time (motor response time and attention).  
The ACTB is becoming increasingly recognised as a suitable cognitive 
assessment battery for people with Down’s syndrome (Patterson et al, 2013; 
Dierssen, 2012) and is starting to be used in the UK as well as in the USA.  
The CANTAB eclipse (Cambridge Neuropsychological Test Automated 
Battery) is a set of computerised cognitive assessment tests designed to 
assess cognitive functions in different domains. It has been developed by 
Cambridge Cognition, who are based in Cambridge, England. Some of the 
CANTAB tests have been used in studies with older adults without dementia 
(Robbins et al, 1994) and in studies with older adults with dementia or mild 
cognitive impairment (Egerhazi et al, 2007; Facal et al, 2009).CANTAB tasks 
have also been used in studies examining other conditions, including 
Schizophrenia, Mania, Depression and Parkinson’s disease.  
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The tests require the use of a touchscreen computer tablet. The computer 
tablet that was used in this study was the Paceblade Slimbook 200, which 
used a Windows XP operating system and has a screen size of 12.1 inches. 
In this thesis, I will refer to the ACTB tests and the table top tests as cognitive 
tests. I will refer to the informant rated assessments as carer rated 
assessments. A number of tasks used in this study, including those from the 
ACTB, table top and carer rated assessments, generate a number of different 
scores and sub-scores that can be used for analysis. Both the CANTAB 
guidance and the original ACTB paper (Edgin et al, 2010a) refer to these as 
outcome measures, and for consistency, I will also refer to them as outcome 
measures in this thesis.  
It should be noted that although NEPSY visuomotor precision is undertaken 
using a pencil and paper, it is part of the Arizona Cognitive Test Battery 
(ACTB), and I have therefore included it within sections on the ACTB. 
2.8.4 Primary outcome  
2.8.4.1 CANTAB Paired Associates Learning (PAL) 
The primary outcome for this study was the CANTAB PAL score. The 
CANTAB PAL measures paired associates learning, which taps into spatial 
associative memory. It has been shown to distinguish between those with 
Alzheimer’s disease and those without Alzheimer’s disease in the general 
population (Swainson et al, 2001) and is being marketed by Cambridge 
Cognition as a tool that General Practitioners can use to detect Alzheimer’s 
disease. It has been used in research with children and adults with Down’s 
syndrome (Oliver et al, 1998; Visu-Petra et al, 2007; Edgin et al, 2010; Edgin 
et al, 2011) and in clinical trials (Boada et al, 2012). 
In this task, participants are shown six white squares, which represent boxes, 
on a touchscreen computer tablet. These open up in turn, revealing patterns 
behind some of the boxes. This is demonstrated in Figure 2.1. Participants 
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then need to identify which pattern was in which box. The stages range from 
1 pattern in 1 of 6 boxes, to 8 boxes each with 8 different patterns. There are 
8 stages in total. Participants have ten trials at each stage before the 
programme will terminate. 
Figure 2.1 – CANTAB PAL 
          
There is a version of the CANTAB PAL for people with Down’s syndrome in 
development, however this was not available at the time that this study was 
conducted. In this study, I used the clinical mode, which is the recommended 
mode to use and was used in the original ACTB study.  
There are several outcome measures generated from this task. I have 
reported two outcome measures in this study: first trial memory score and 
stages completed. First trial memory score gives the number of patterns 
correctly identified at the participant’s first trial or attempt. This is the outcome 
measure reported in the ACTB study and is the outcome measure I based 
my power calculation on. However, in this study, a more appropriate outcome 
measure to use was stages completed, which refers to the number of stages 
which were completed by the participant and has a better spread of data in 
my study sample. I have therefore reported both of these outcome measures 
in this thesis. 
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2.8.5 Secondary outcomes  
2.8.5.1 ACTB tests 
2.8.5.1.1 CANTAB Intra-Extra Dimensional Shift (IED) 
This is a measure of prefrontal function and measures set shifting. In this 
task, participants are shown a computer screen with two purple patterns. 
Participants are asked to work out the rule and press the box with the pattern 
in it that they have identified as “right”. Once participants have identified the 
rule, the rule then changes and participants have to work out the new rule. 
The test becomes increasingly complex and more advanced stages include 
white lines as well the purple patterns. Figure 2.2 shows the CANTAB IED.  
Participants need to have 6 consecutive correct responses before moving to 
the next stage. If they are unable to reach this after 50 trials, the task ends. 
Different stages are reported to assess different cognitive functions. The first 
stage measures simple discrimination learning and the second stage 
measures reversal learning. The intra dimensional shift occurs at stage 6, 
when new patterns and lines are displayed. The rule is still based on 
identifying what the “right” pattern is. The extra dimensional shift occurs when 
participants have to identify that the new rule depends on the white line 
rather than the pattern. This occurs at stage 8. There are 9 stages in total. 
There are several outcome measure in this task. The outcome measures 
used in this study are stages completed and errors block 1. Errors block 1 
refers to the number of errors made in the first stage, which measures simple 
discrimination learning. I used the clinical mode for this task. 
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Figure 2.2 - CANTAB IED 
 
As well as being used in the ACTB, this task has been used in research with 
young adults with Down’s syndrome and young adults with Fragile X 
syndrome in the Netherlands (van der Molen et al, 2012). 
2.8.5.1.2 Modified dots task (Cats and Frogs) 
This is a computer based task developed by the Department of Psychology, 
University of Arizona. It is a test of inhibitory control and working memory. In 
the first stage of the task, participants are taught a rule for which button to 
press when a picture of a cat comes on the screen (press the button directly 
below the cat). They are then taught a new rule for when a frog comes on the 
screen (press the button on the opposite side of the screen from the frog). In 
the third and final stage of this task, participants are then required to shift 
between the cat and frog rules when either cats or frogs are shown on the 
screen.   
This task requires the computer software Presentation (www.neurobs.com), 
in order to run. The outcome measures used in this study are percentage of 
correct presses in the 2nd stage, when participants need to learn the reverse 
of the previous rule and percentage of correct presses in the 3rd stage, when 
participants need to switch between the cat and frog rules. 
This task has been used in children and young adults with Down’s syndrome 
in the USA (Edgin et al, 2010a).  
58 
2.8.5.1.3 CANTAB Simple Reaction Time (SRT) 
This task was designed by CANTAB to be a measure of attention, but was 
incorporated into the ACTB as a measure of cerebellar function and 
assesses motor response time. Participants are shown a black computer 
screen. At times, a white square appears in the centre of the screen. This is 
demonstrated in Figure 2.3. Participants are asked to press a button on a 
press pad as soon as they see the white square. There is a variable time in 
between when the white square appears on the screen.  
There are three sections in this task, which do not change in degree of 
difficulty. The score for analysis that was used in this study was the median 
latency score. Other scores that are available to use include number of 
correct trials (out of a total of 124 trials), which can give a measure of 
attention.  
Figure 2.3 – CANTAB SRT 
     
2.8.5.1.4 Finger sequencing task (Fingertapping) 
This is a computer based task that assesses motor sequencing. It is based 
on the NEPSY fingertapping task, but was adapted by the Department of 
Psychology, University of Arizona to a computer-based version as there was 
a poor level of compliance with the table-top task. In the computer version, 
participants are asked to help the dog “run” to his food by tapping the lever.  
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It measures finger sequencing generated by tapping a number of fingers 
(from 1 to 4) on both hands to a lever in succession. The Finger sequencing 
task has the potential to generate a number of outcome measures, but this 
requires at least two researchers for scoring. I therefore obtained one simple 
outcome measure for this task. The score I used for analysis was maximum 
sequences reached. 
In this study, I used a computer mouse for the first 7 participants. As 
participants were not familiar with using a computer mouse, they found this 
difficult. This was therefore changed to a lever made by the Department of 
Psychology, University of Arizona. For completeness, I have included data 
using both the mouse and the lever in this analysis. 
2.8.5.1.5 NEPSY visuomotor precision 
This is a table-top test that was included in the ACTB to assess visuo-motor 
tracking and hand-eye coordination. It is part of the NEPSY II (developmental 
NEuroPSYchological assessment) (Korkman et al, 2007), which is another 
battery of tests of cognitive abilities designed for children.  
In this task, participants are asked to draw a line around a track, without 
going outside the track lines and without turning the paper. There are three 
tracks to complete. The width, length and complexity of the track increase 
with each track. Participants are assessed on number of errors and time 
taken. A score is then calculated using NEPSY tables, which takes into 
account errors and time taken. In this study, I used two outcome measures: 
one that is calculated using the first and second tracks – train and car 
(designed for typically developing children aged 3 to 4 and used in the 
original ACTB paper analyses) and one that is calculated using the second 
and third tracks – car and motorbike (designed for typically developing 
children aged 5 to 12). 
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2.8.5.2 Table top tests 
2.8.5.2.1 Verbal fluency 
This assesses initiation and set shifting and was selected from the 
CAMCOG-DS assessment battery (Ball et al, 2006b). In this task, 
participants are asked to name as many animals they can think of in one 
minute. Repetitions were recorded but did not contribute to the total score. 
The total number of animals is then adjusted using a scale, where 1-5 
animals = 1, 6-10 animals = 2, 11-15 animals = 3 and 16 and over = 4. The 
outcome measures I have used in this thesis are the raw score and adjusted 
score.  
2.8.5.2.2 Tower of London 
This is a test of executive function and specifically assesses working memory 
and planning (Shallice, 1982). The test used was adapted for use with people 
with intellectual disability from Strydom et al (2007). In this task, the 
researcher and participant both have a board with a green, a red and a blue 
ball in a specific starting position. In the teaching phase, participants are 
shown a 1 move configuration on the researcher’s board and are asked to 
move the balls in order to make their board look like the one the researcher 
has.  
In the test phase, participants have to work out how to make other 
configurations with as few moves as possible. They are not allowed to move 
more than one ball at any one time. In this study, there were two 2- and 3-
move configurations and one 4-move configuration. The Tower of London 
test is demonstrated in Figure 2.4. In Figure 2.4, moving the balls from the 
position in the left hand picture to the position in the picture on the right takes 
a minimum of four moves.  
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Figure 2.4 – Tower of London 
      
This task was scored by awarding 1 point for each configuration correct in 
more than the minimum moves and 2 points if it was completed in the 
minimum number of moves. The maximum score available was 10. I used 
two outcome measures in this study: points and stages completed. 
2.8.5.2.3 NAID Object memory 
This is a test of object memory. It forms part of the Neuropsychological 
Assessment of age related cognitive deficits in Adults with Down’s syndrome 
(NAID), which is a battery of cognitive tests for people with intellectual 
disability often used in clinical practice and research (Crayton et al, 1998).  
In the Object memory task, participants are shown ten everyday items (these 
are: a comb, a key, a letter, a 10p coin, a spoon, a watch, a notepad, a 
purse, a pencil and a toothbrush). They are asked to name them. Any items 
participants are not able to name are not used in testing.  
In the teaching stage, participants are shown 2 items and are again asked to 
name them. One item is then covered and participants need to name the item 
that is covered. This is repeated using 3 items. 
In the testing stage, two items are displayed and participants are asked to 
name them. Whilst the participant is looking away, one item is covered. 
Participants are asked to name which item is covered. This is repeated with 
another two items. This is then repeated with 3, 4, 5 and 6 items. There are a 
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total of 10 trials (i.e. 2 trials for each number of items). Between each trial, I 
changed a selection of items.  
The outcome measure for this task is number of items remembered. The 
maximum score is 10. 
Figure 2.5 – NAID Object memory 
 
2.8.5.2.4 NAID Memory for sentences 
This assesses verbal memory and is also part of the NAID. During the 
teaching phase, the assessor asks the participant to repeat the words 
“watch” and “lamp” back to them. During the testing phase, participants are 
asked to repeat back a sentence. The sentences get progressively longer. 
Participants are scored on how many words in the sentence they are able to 
repeat. The maximum score for this task is 48.  
Object memory, Memory for sentences, Verbal fluency and the Tower of 
London test have previously been used in a study with older people with 
Down’s syndrome (Ball et al, 2008). The standardised NAID manual is yet to 
be published. 
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2.8.5.2.5 Standardised Finger-nose test 
This is a clinical test used to assess cerebellar function. Participants are 
asked to touch their nose and then touch a red spot of 2cm diameter which is 
45 cm away from them. The outcome measure is the number of times they 
can do this in 20 seconds. 
This standardised version has been used to assess motor coordination in 
older adults in the general population (Desrosiers et al, 1995). 
2.8.5.2.6 Gait assessment 
To assess gait, I used the timed up and go test. This is a clinical assessment 
that can be used to assess balance, and includes rising, walking and turning. 
Participants are timed to see how long it takes for them to get up from a 
chair, walk a distance of 3 meters, turn around, walk back to the chair and sit 
back down (Podsiadlo and Richardson, 1991). Participants have one practice 
and then two testing trials. An average of the two testing trials is the outcome 
measure. Where participants were only able to complete the practice trial, 
this was included in the analysis for completeness. 
2.8.5.3 Carer rated assessments 
2.8.5.3.1 Dementia Questionnaire for people with Learning Disabilities (DLD) 
This is a carer rated questionnaire which is often used clinically to assist in 
the identification of dementia in people with intellectual disabilities (Evenhuis, 
1992; Evenhuis, 1996). Carers are asked to rate various items relating to the 
cognitive and social function of the individual with intellectual disability over 
the past two months. Sums of cognitive scores (SCS) and sums of social 
scores (SSS) are calculated, which combine to form a total score. A 
deterioration in score can help clinicians when making a diagnosis of 
dementia. A higher score is indicative of increased difficulties. Sub-sections 
of the Cognitive Scores are Short Term Memory (STM), Long Term Memory 
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and Spatial and Temporal Orientation. Sub-sections of the Social Scores are 
Speech, Practical skills, Mood, Activity and Interest and Behavioural 
disturbance. The maximum scores for sum of cognitive and social scores are 
44 and 60 respectively, making a maximum total score of 104. 
The DLD was previously known as the DMR (Dementia Questionnaire for 
persons with Mental Retardation). The DLD has been used extensively both 
clinically and in research with people with intellectual disabilities, including 
those with Down’s syndrome (Strydom and Hassiotis, 2003; Strydom et al, 
2007; Lott et al, 2012).  
2.8.5.3.2 Behaviour rating inventory for executive function (BRIEF) 
The BRIEF - Parent Form (Behaviour Rating Inventory of Executive Function) 
is a carer rated assessment of executive function (Gioia et al, 2000). It is an 
86 item questionnaire for use for people between 5-18 years. It takes 
approximately 10 -15 minutes to administer and 20 minutes to score. Carers 
rate behaviours in the past 6 months according to whether the behaviour has 
occurred Never, Sometimes or Often. Results are then calculated to generate 
8 subscale scores. These are: Inhibit, Shift and Emotional control (which 
make up the Behavioural Regulation Index (BRI)), and Initiate, Working 
memory, Plan/organise, Organisation of materials and Monitor (which make 
up the Metacognition Index (MI)). Together, the Behavioural Regulation Index 
and the Metacognition Index make up the Global Executive Composite 
(GEC). There are parent rated, teacher rated, pre-school and adult versions 
of the BRIEF. In this study, I adapted the parent version for use in an adult 
population. This measure has not been validated in an adult population, but 
has been used in the original ACTB study (Edgin et al, 2010a). 
Results are not valid if more than 14 questions are not answered and 
questionnaires that had more than 14 questions not answered were not used 
in the analysis. Some questions are also used to generate Negativity and 
Inconsistency scales, which can be used to help the researcher when 
considering validity. The negativity scale is scored as acceptable, elevated or 
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highly elevated. A highly elevated negativity scale implies that raters have 
reported a number of questions negatively. The inconsistency scale is scored 
as acceptable, questionable or inconsistent. Where participants had a highly 
elevated negativity score and an inconsistency score of 
questionable/inconsistent, or an elevated/highly elevated negativity score and 
an inconsistency score of inconsistent, the BRIEF scores were removed from 
the analysis.  
Raw scores should then be converted to population-based percentiles. As 
the published percentiles are based on children and this study was 
conducted with adults, I used the raw scores in my analysis.  
2.8.5.3.3 PAS-ADD checklist  
The PAS-ADD checklist is a clinical screening tool that has also been used in 
research to screen for mental health problems (Moss et al, 1998). Carers are 
asked to rate symptoms over the past 4 weeks. Scores are rated as to 
whether a participant has passed the threshold score for each specific 
category.  
Although designed for clinical practice, the PAS-ADD checklist has been 
used in a number of studies with people with intellectual disabilities (Cooper 
et al, 2009b), including those with Down’s syndrome (Mantry et al, 2008). 
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2.8.6 Summary of cognitive assessments 
Table 2.1 shows a summary of the cognitive assessments used in this study. 
Table 2.1 – Summary of cognitive assessments 
 ACTB Table top tests 
Carer rated 
assessments 
Prefrontal CANTAB IED (Intra-
Extra Dimensional 
Shift) 
Verbal fluency 
(CAMCOG-DS) 
BRIEF 
 Modified dots task 
(Cats and Frogs) 
Tower of 
London 
 
Hippocampal CANTAB PAL 
(Paired Associates 
Learning) 
Object memory 
(NAID) 
DLD 
  Memory for 
sentences 
(NAID) 
 
Cerebellar CANTAB SRT 
(Simple Reaction 
Time) 
Standardised 
Finger-nose test 
 
 Finger sequencing 
task (Fingertapping) 
Gait 
assessment 
 
 NEPSY visuomotor 
precision 
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2.8.7 Other tests 
2.8.7.1 K-BIT II 
The K BIT II (Kaufman Brief Intelligence Test) is a measure of verbal and 
non-verbal intelligence and is appropriate for use for people between 4 and 
90 years of age (Kaufman and Kaufman, 2004).  
It is a global cognitive measure that has been used by the Down’s syndrome 
research group in the University of Arizona and is being used in similar 
studies. It mainly relies on non-verbal responses, so somewhat accounts for 
the weaker verbal skills often seen in people with Down’s syndrome. It has 
been used widely in US populations and the K-BIT has recently been used in 
a UK sample of people with intellectual disability (Tyrer et al, 2010). 
The K-BIT II generates separate verbal and non verbal raw subscales, which 
are combined to give a total raw score. These should then be converted to 
population norms, however, a large proportion of participants in my sample 
would have scored at floor, as the K-BIT II is not able to determine the level 
of IQ below 40. I therefore used the raw scores in my analysis. The original 
ACTB paper also uses raw K-BIT scores. 
2.8.7.2 CANTAB MOT (Motor Screening Task) 
This is a CANTAB teaching test, designed to assess whether participants are 
able to use the touchscreen computer tablet. Participants are shown flashing 
crosses on a screen and the researcher demonstrates how to make them 
disappear by touching them. Then participants are asked to try to make the 
crosses disappear by touching them. Participants were given several 
attempts to do this task. If they were not able to touch the cross on at least 
one occasion, they were seen as not passing the teaching stage for the 
computer tasks and did not attempt the rest of the computer-based tasks. In 
this study, I used the high visibility mode. Figure 2.6 shows the CANTAB 
MOT computer screen. 
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 Figure 2.6 – CANTAB MOT 
 
2.8.7.3 Physical health tests 
In order to obtain basic measures of health, I obtained blood pressure and 
pulse readings as well as abdominal circumference. If participants or their 
carers had recent weight and height measurements, I obtained these as well. 
Weight and height were converted into metric units if applicable. 
2.8.7.4 Data Collection 
Demographic and other important information was collected on a data 
collection form. This included: 
- Demographic details - Age, Gender, Ethnic origin, type of 
accommodation, family history of Down’s syndrome, family history of 
dementia 
- Level of intellectual disability and premorbid cognitive level (IQ), if 
known 
- Medical problems (including hypothyroidism, epilepsy, history of CVA, 
falls) 
- Psychiatric history 
- Sensory impairments 
- Medication 
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2.8.7.4.1 Dementia diagnosis 
Dementia diagnosis was obtained by asking at the time of assessment if the 
participant had a diagnosis of dementia. Where applicable, the status of a 
dementia diagnosis at the time of assessment, (or subsequently made by the 
treating clinician directly based on the findings of the assessment) was 
clarified from the clinical notes and/or by discussing this with the participant’s 
treating clinician. A consensus dementia diagnosis was then decided on by 
myself in consultation with my primary supervisor (ASt), taking into account 
the treating clinician’s dementia diagnosis and other relevant factors such as 
new onset of epilepsy.  
Participants were categorised into either a “dementia” or “no dementia 
group”. Those in the dementia group had a diagnosis of dementia or possible 
dementia. Those in the no dementia group had no diagnosis of dementia. 
Some participants in the no dementia group had symptoms of cognitive 
concern, which may have been explained by other factors or were not 
enough to warrant a diagnosis of dementia. 
2.9  Analysis  
Data were entered into a database using SPSS version 21. The majority of 
the analyses were conducted using SPSS. Stata IC12 was used to calculate 
the median difference and 95% confidence intervals for the non-parametric 
analyses. 
2.9.1 Demographics  
I initially described the demographic profiles of the total sample and then 
looked for any differences between those with dementia and those without 
dementia. 
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2.9.2 Feasibility 
Feasibility tests were used to assess the psychometric properties of the 
computer and table top tests. These included looking at the percentage of 
participants who were able to attempt the tests and the spread of the results. 
I examined these properties initially by looking at the total sample and then I 
looked separately at the dementia and no dementia groups. 
I calculated the percentage of participants at floor and ceiling for each of the 
tasks. For the majority of the tasks, floor was calculated as a score of zero 
(for: K-BIT II total raw score, K-BIT II verbal and non verbal subscales, 
CANTAB PAL stages completed and first trial memory score, CANTAB IED 
stages completed, Finger sequencing task, NEPSY visuomotor precision, 
Verbal fluency raw score and adjusted and Finger-nose test). For NAID 
Object memory, NAID Memory for sentences, Tower of London points and 
stages completed, floor was calculated as a score of zero and/or did not pass 
teaching stage. For Gait assessment, floor was calculated as being unable to 
mobilise without assistance. 
In the modified dots task, floor was calculated as 50% or under (as 50% of 
responses should be correct by chance alone). CANTAB SRT median 
latency is measured in units of time and, as it is on a continuum, floor and 
ceiling levels are not applicable.  
Where applicable, ceiling levels were calculated as maximum possible score. 
Many of the computer based tests and some of the table top tests generated 
several different outcome measures. In order to identify the most valid 
outcome measures and ones that retained the most amount of information, I 
initially narrowed them down to the ones that had good face validity, for 
example, some of the CANTAB outcome measures provide adjusted scores 
that would not be valid if the majority of participants did not complete all 
levels of the task. I also discussed which would be the most appropriate 
measures to use with one of the authors of the ACTB. 
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Following data collection, I looked at the range and spread of the data for the 
relevant outcome measures as well as the proportion of those at floor and 
whether those at floor were able to be used in data analysis or not. In 
consultation with my primary supervisor (ASt), we came to a consensus 
about which outcome measure for each test would be the most appropriate to 
use. Alongside this, I also considered which outcome measures were 
commonly used in the relevant literature in this population. 
Where it was not clear what the most appropriate outcome measure was to 
use for a specific test, I have reported data on more than one outcome 
measure. 
The spread of the data and distribution was assessed using box and whisker 
plots. The majority of data was not found to be normally distributed and 
therefore non-parametric statistical tests are used for the majority of 
analyses.   
2.9.3 Differences between dementia and no dementia groups 
2.9.3.1 Primary analysis 
My primary outcome was the difference in the CANTAB PAL first trial 
memory score between the dementia and no dementia groups. I also 
analysed CANTAB PAL stages completed.   
2.9.3.2 Secondary analyses 
Following my primary analysis, I examined the differences between the 
dementia and no dementia groups in the other cognitive tests, including the 
scores of the other tests in the ACTB. As the data was not normally 
distributed, on the recommendation of the statistician assisting in this study 
(KR), this was assessed by examining the median difference and 95% 
confidence intervals between the two groups. 
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2.9.3.3 Analyses adjusting for confounders 
For the cognitive tests where the 95% confidence intervals for the median 
difference between the dementia and no dementia groups did not include 
zero, I then used appropriate statistical models to identify whether a 
statistically significant difference remained when accounting for age and 
gender. 
2.9.4 Concurrent validity 
I assessed the relationship between the tests in the ACTB and other 
measures of cognitive function (table top tests and carer ratings) using 
correlation.  I calculated the Spearman’s rank correlation coefficient between 
the ACTB, table top and carer rated tests that assessed prefrontal, 
hippocampal and cerebellar function. 
2.10  Summary 
Adults with Down’s syndrome aged 45 and over were recruited. Specific 
cognitive skills of participants with Down’s syndrome were assessed using a 
number of cognitive tests. The assessment lasted between 2-3 hours and 
was arranged at a location that was convenient for the participant and their 
carer. 
The assessment included computer-based tests (the Arizona Cognitive Test 
Battery, ACTB) and table-top tests, which were designed to assess cognitive 
function in the prefrontal, hippocampal and cerebellar areas. Alongside this, 
carers or relatives completed carer-rated questionnaires. 
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Chapter 3. Results 
3.1 Overview 
The main aim of this study was to assess the use of the ACTB in older adults 
with Down’s syndrome and establish its validity in testing for dementia. I will 
begin this chapter by describing the demographic characteristics of the 
sample. I will then present results regarding feasibility of the tasks as well as 
examining differences between the dementia and no dementia groups. I will 
conclude by describing the concurrent validity of the tasks. 
3.2 Flow diagram 
Figure 3.1 summarises the flow of participants in the study. As the first stage 
of recruitment was conducted by local learning disability teams and day 
centres, there is no record of how many people were initially considered for 
participation in the study. 
Please note, when reporting and discussing my results, I will refer to the two 
groups as “dementia” and “no dementia” groups, however participants in the 
“dementia” group had a diagnosis of dementia or possible dementia and 
participants the “no dementia” group included some participants with 
symptoms of cognitive concern, which may have been explained by other 
factors or were not enough to warrant a diagnosis of dementia. 
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Figure 3.1 - Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 participants participated in the 
study 
75 people contacted by 
researcher 
19 with dementia or 
possible dementia 
31 with no dementia 
Reasons not entered into 
study: 
Unable to attempt cognitive 
tests (7) 
Did not want to take part (5) 
Unable to arrange 
assessment before 
recruitment end date (4) 
Significant sensory 
impairment (2) 
Below age limit (2) 
Unclear diagnosis of Down’s 
syndrome (2)  
Deceased (2) 
Behavioural problems (1) 
Potential participants approached by 
learning disability teams and day centres 
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3.3 Demographics 
50 participants were recruited into the study. Of these, 23 (46%) were male 
and 27 (54%) were female. Participants were recruited from the London 
Boroughs of Islington, Camden, Haringey, Westminster, Brent, Enfield, 
Hillingdon, Harrow and Kensington and Chelsea. The mean age at first 
assessment was 53.01 years (SD: 6.34) and the median age was 50.85 
years (range: 45.14 – 67.13 years).  
Average age at first assessment for the dementia group was mean 55.64 
years (SD 6.77), median 55.04 years (range: 45.37 - 64.88 years). Age at 
first assessment for the no dementia group was mean 51.40 years (SD: 
5.58), median 50.20 years (range 45.14 - 67.13 years). 
There was a significant difference in age of participants between the 
dementia and non dementia groups, with participants in the dementia group 
being older. There was no significant difference in gender, level of intellectual 
disability, ethnic origin or type of accommodation between the two groups. 
Three participants had a diagnosis of mosaic Down’s syndrome documented 
in the clinical notes. Of these participants, one had a diagnosis of dementia.  
Table 3.1 shows further detail on demographic characteristics of the group. 
Demographic data for the whole group as well as data for the dementia and 
no dementia groups are shown separately. The numbers in brackets are 
percentages within each group. The p-value refers to the Chi-squared or 
Fisher’s exact test used to identify any significant differences between the 
dementia and no dementia groups. 
The Fisher’s exact p value for age as a categorical variable is shown in Table 
3.1. When age was analysed as a continuous variable using the Independent 
samples Mann Whitney U test, the significance level was also p=0.049. 
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Table 3.1 - Demographic characteristics of the study sample 
  Whole group/n (%) Dementia/n (%) No Dementia/n (%) P value 
Gender Male 23/50 (46.0%) 12/19 (63.2%) 11/31 (35.5%)  
 Female 27/50 (54.0%) 7/19 (36.8%) 20/31 (64.5%) 0.057a 
Age Below 50 20/50 (40.0%) 6/19 (31.6%) 14/31 (45.2%)  
 50 – 54 14/50 (28.0%) 3/19 (15.8%) 11/31 (35.5%)  
 55 – 59 5/50 (10.0%) 2/19 (10.5%) 3/31 (9.7%)  
 60 and over 11/50 (22.0%) 8/19 (42.1%) 3/31 (9.7%) 0.049b* 
Premorbid Level of ID     
 Mild 13/35 (37.0%) 5/14 (35.7%) 8/21 (38.1%)  
 Moderate/Severe 22/35 (63.0%) 9/14 (64.3%) 13/21 (61.9%) 0.886a 
Ethnic origin White 41/49 (83.7%) 17/19 (89.5%) 24/30 (80.0%)  
 African/Afrocaribbean 4/49 (8.2%) 1/19 (5.3%) 3/30 (10.0%)  
 Other 4/49 (8.2%) 1/19 (5.3%) 3/30 (10.0%) 0.738b 
Type of Accommodation     
 Family or friends 14/50 (28.0%) 6/19 (31.6%) 8/31 (25.8%)  
 Adult placement 7/50 (14.0%) 1/19 (5.3%) 6/31 (19.4%)  
 Supported accommodation 29/50 (58.0%) 12/19 (63.2%) 17/31 (54.8%) 0.428b 
a
 Chi Squared value,
 b
 Fisher’s exact value, *Significant at the 0.05 level 
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Figure 3.2 shows the numbers of participants with and without dementia 
recruited from each site. 
Figure 3.2 - Bar chart to show participants recruited from each site 
 
3.3.1 Physical Health 
Five participants had hypercholesterolaemia and two had a history of 
hypertension. One participant had a diagnosis of diabetes (diet controlled 
Type II diabetes) and two participants were smokers. Thirteen participants 
had skin problems, including psoriasis and dermatitis. Five participants had 
abdominal problems, including abdominal pain and irritable bowel syndrome. 
Two participants were on anticoagulant treatment for deep vein thrombosis 
(DVT). 
None of the participants had a confirmed history of stroke or head injury, 
although details of history of stroke were missing in two participants and 
details of history of head injury were missing in four participants. One 
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informant was uncertain as to whether the participant had a history of head 
injury. 
One participant had possible congenital cardiovascular problems and one 
participant had possible hearing problems. These data have been taken out 
for the purpose of the analyses in the table below. 
The frequency of physical health problems associated with Down’s syndrome 
or dementia are described in Table 3.2. Median data for physical health 
measures are reported in Table 3.3. 
Table 3.2 - Physical health conditions of the study sample 
 Whole 
group/n 
(%) 
Dementia/n 
(%) 
No 
Dementia/n 
(%) 
P value 
Thyroid problems 
20/49 
(40.8%) 
7/18 
(38.9%) 
13/31 
(41.9%) 
0.834a 
Epilepsy 
9/49 
(18.4%) 
5/19 
(26.3%) 
4/30   
(13.3%) 
0.282b 
Falls 
9/45 
(20.0%) 
4/16 
(25.0%) 
5/29   
(17.2%) 
0.700b 
Congenital 
Cardiovascular 
problems 
5/48 
(10.4%) 
2/18 
(11.1%) 
3/30      
(10.0%) 
1.000b 
Hearing problems 
8/47 
(17.0%) 
5/18 
(27.8%) 
3/29    
(10.3%) 
0.230b 
Visual problems 
23/49 
(46.9%) 
10/19 
(52.6%) 
13/30 
(43.3%) 
0.525a 
Family history of 
dementia 
7/33 
(21.2%) 
1/12  
(8.3%) 
6/21   
(28.6%) 
0.223b 
 
 
a
 Chi Squared value 
b
 Fisher’s exact value 
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Table 3.3 - Physical health measures of the study sample 
 Whole 
group 
Median 
(Range) 
Dementia 
Median 
(Range) 
No 
Dementia 
Median 
(Range) 
P value c 
Pulse (bpm) 
n=36 
64.5    
(42.0-93.5) 
65.5    
(52.0-82.0) 
63.0    
(42.0-93.5) 
0.713 
Diastolic BP 
(mmHg) 
n=36 
71.5    
(58.0-100.0) 
74.8    
(63.5-100.0) 
70.8    
(58.0-92.0) 
0.160 
Abdominal 
circumference 
(cm) 
n=40 
101.3  
(83.0-136.0) 
97.0    
(83.0-115.0) 
107.0   
(85.0-136.0) 
0.039* 
Weight (kg) 
n=25 
72.1    
(49.0-136.5) 
64.9    
(56.3-82.0) 
82.6    
(49.0-136.5) 
0.344 
 
There were no significant differences in common physical health conditions 
between the dementia and no dementia groups. There was no significant 
difference in pulse, diastolic blood pressure or weight between the two 
groups, although there was a significant difference in abdominal 
circumference, with those in the no dementia group having a larger 
abdominal circumference. 
c
 Independent samples Mann Whitney U test 
* Significant at the 0.05 level 
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3.3.2 Mental Health 
Table 3.4 shows the frequency of mental health problems in the study 
sample. One participant had a history of Bipolar Affective Disorder.  
Table 3.4 - Mental health conditions in the study sample 
 Whole 
group/n 
(%) 
Dementia/n 
(%) 
No 
Dementia/n 
(%) 
P value 
History of 
Psychosis 
7/46 
(15.2%) 
1/17     
(5.9%) 
6/29     
(20.7%) 
0.234b 
History of 
Depression 
15/46 
(32.6%) 
4/17    
(23.5%) 
11/29    
(37.9%) 
0.315a 
Above PAS-ADD checklist threshold for:  
Possible   
organic 
condition 
8/49 
(16.3%) 
4/18   
(22.2%) 
4/31     
(12.9%) 
0.443b 
Affective or 
neurotic 
disorder 
10/49 
(20.4%) 
6/18   
(33.3%) 
4/31     
(12.9%) 
0.141b 
Psychotic 
disorder 
8/49 
(16.3%) 
5/18   
(27.8%) 
3/31       
(9.7%) 
0.124b 
 
There were no significant differences in history of mental health problems 
between the two groups, however there was a higher percentage of 
participants with a history of depression and psychosis in the non-dementia 
group. There were no significant differences in new mental health symptoms 
detected in the four weeks prior to the assessment, as determined by the 
PAS-ADD checklist. 
a
 Chi Squared value 
b
 Fisher’s exact value 
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3.4 Feasibility  
In order to evaluate feasibility of the cognitive tests, I initially examined the 
proportion of participants who were able to attempt each of the ACTB and 
table top tasks. These results are shown in Table 3.5. 
Table 3.5 - Proportion of participants that attempted each cognitive task 
Measure 
 
Total attempted 
n=50 
Dementia 
 n=19 
No dementia 
n=31 
ACTB tests:    
CANTAB IED 45 (90.0%) 15 (78.9%) 30 (96.8%) 
Modified dots task 40 (81.6%)e 13 (68.4%) 27 (90.0%) 
CANTAB PAL 45 (90.0%) 15 (78.9%) 30 (96.8%) 
CANTAB SRT 47 (94.0%) 18 (94.7%) 29 (93.5%) 
Finger sequencing 
task 
44 (89.8%)e 15 (79.0%) 29 (96.7%) 
NEPSY visuomotor 
precision 
41 (82.0%) 12 (63.2%) 29 (93.5%) 
Table top tests:    
Verbal fluency 44 (88.0%) 14 (73.7%) 30 (96.8%) 
Tower of London 37 (74.0%) 11 (57.9%) 26 (83.9%) 
Object memory 34 (68.0%) 12 (63.2%) 22 (71.0%) 
Memory for 
sentences 
43 (86.0%) 14 (73.7%) 29 (93.5%) 
Finger-nose 41 (82.0%) 14 (73.7%) 27 (87.1%) 
Gait assessment 38 (76.0%) 12 (63.2%) 26 (83.9%) 
 
Of the ACTB tasks that were not attempted, a range from 1 (2%) to 3 (6%) of 
participants did not pass the teaching stage and from 1 (2%) to 4 (8%) 
participants refused to attempt the task. The CANTAB SRT and Finger 
e n=49 
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sequencing task were not administered on one occasion and the NEPSY 
visuomotor precision and Modified dots task on 2 and 3 occasions 
respectively. A technical issue prevented the CANTAB PAL task to be 
attempted on one occasion and the Modified dots task on two occasions and 
prevented results from being recorded from the Modified dots task on 7 
occasions. 
Of the table top tasks that were not attempted, a range from 2 (4%) to 6 
(12%) of participants refused to attempt the task and from 1 (2%) to 8 (16%) 
participants did not pass the teaching stage. 4 people with dementia and 4 
people without dementia did not pass the teaching stage for Object memory. 
Verbal fluency was not administered on one occasion, Memory for sentences 
and finger-nose on 2 occasions, Tower of London on 3 occasions and Object 
memory on 4 occasions. Gait assessment was not conducted on 5 occasions 
and a further 3 participants did not attempt the task, as they were not able to 
mobilise without assistance.  
10 (52.6%) people with dementia were able to attempt all the ACTB tasks 
and 10 (52.6%) were able to attempt all the table top tasks. 24 (77.4%) 
people in the no dementia group were able to attempt all the ACTB tasks and 
21 (67.7%) attempted all the table top tasks. 
Table 3.6 shows the distribution data for the cognitive measures. As the 
outcome measures did not display a normal distribution, both the mean and 
median are reported.  
I calculated percentage of participants at floor and ceiling for each of the 
tasks. See Method section 2.9.2 for further details regarding how floor and 
ceiling levels were determined. It is noted that some of the n for outcomes 
are larger than n reported in Table 3.5. This is because some outcome 
measures may include data from teaching phases of the tasks. Other 
outcome measures may have a lower n than reported in Table 3.5. This is 
because they may require completion up to a certain stage of the task and 
therefore do not include participants at floor. 
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Table 3.6 - Distribution data for cognitive measures 
Measure N Mean 
(SD) 
Median 
(Range) 
 
Number 
at floor  
Number 
at ceiling  
 
K-BIT II: 
     
Total raw score 50 17.72 
(17.77) 
9.50       
(1-63) 
0    
(0.0%) 
0    
(0.0%) 
Verbal subscale raw 
score 
50 12.42 
(12.26) 
7.5         
(0-47) 
1     
(2.0%) 
0    
(0.0%) 
Non verbal subscale 
raw score 
50 5.30 
(6.19) 
2.0         
(0-20) 
10 
(20.0%) 
0    
(0.0%) 
 
ACTB tests: 
CANTAB IED:      
  Stages completed 45 1.76 
(2.68) 
0             
(0-8) 
24 
(53.3%) 
0   
(0.00%) 
  Errors block 1 45 14.67 
(11.33) 
15          
(0-32) 
n/a 6   
(13.3%) 
Modified dots task:      
  2nd stage (frogs) 33 0.42 
(0.29) 
0.33    
(0.0-1.0) 
25 
(75.8%) 
4   
(12.1%) 
  3rd stage (combined) 33 0.39 
(0.17) 
0.39     
(0.3-0.91) 
26 
(78.8%) 
0     
(0.0%) 
CANTAB PAL:      
  Stages completed 45 2.56 
(2.20) 
2            
(0-8) 
6   
(13.3%) 
2     
(4.4%) 
  First trial memory            
score 
45 2.22 
(3.25) 
1            
(0-15) 
17 
(37.8%) 
n/a 
CANTAB SRT median 
latency 
45 1317.62
(614.37) 
1300.50 
(351-2408) 
n/a n/a 
Finger sequencing 
task 
43 1.72  
(1.03) 
1             
(0-4) 
1     
(2.3%) 
5   
(11.6%) 
NEPSY visuomotor 
precision: 
     
  Train and car 36 10.08  
(6.073) 
11          
(1-21) 
0      
(0.0%) 
0     
(0.0%) 
  Car and motorbike 34 7.62  
(7.742) 
4            
(0-28) 
1       
(2.9%) 
0          
(0.0%) 
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Measure N Mean 
(SD) 
Median 
(Range) 
 
Number 
at floor  
Number 
at ceiling  
 
Table top tests: 
Verbal fluency:      
  Raw score 44 5.09  
(4.03) 
5            
(0-17) 
7  
(15.9%) 
n/a 
  Adjusted 44 1.48 
(0.93) 
2            
(0-4) 
7  
(15.9%) 
n/a 
Tower of London:      
  Stages completed 43 2.02 
(1.24) 
2            
(0-4) 
6   
(14.0%) 
6  
(14.0%) 
  Points 37 3.65 
(3.04) 
3             
(0-10) 
14 
(32.6%) 
2     
(4.7%) 
Object memory 34 5.38 
(2.92) 
6            
(0-10) 
11 
(26.2%) 
2 (4.8%) 
Memory for sentences 43 12.81 
(10.76) 
10          
(0-44) 
4     
(8.5%) 
0     
(0.0%) 
Finger-nose 41 6.32  
(4.14) 
6            
(1-19) 
0.0     
(0%) 
n/a 
Gait assessment 38 14.61  
(4.93) 
14.14 
(6.53-
25.93) 
3     
(7.3%) 
n/a 
Table 3.6 continued – Distribution data for cognitive measures  
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The floor and ceiling effects vary from test to test, although the CANTAB IED 
stages completed and Modified dots task have a very large number of 
participants at floor.   
Figures 3.3, 3.4 and 3.5 show boxplots comparing the outcome measures 
from these cognitive tasks in the dementia and no dementia groups. From 
these it is possible to examine the spread of the data and any differences in 
the medians and interquartile ranges of the dementia and no dementia 
groups. 
As data is not symmetric around the median, it can be seen that the data 
does not fit a normal distribution and therefore non-parametric analyses were 
conducted. See Appendix Table A1 for skewness and kurtosis of these data, 
providing further information regarding the spread of the data. 
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Figure 3.3 - Boxplots to show differences between dementia and no dementia groups - K-BIT II scores 
 
K-BIT II total Raw Score 
 
 
 
 
K-BIT II verbal subscale Raw Score 
 
 
 
 
K-BIT II Non verbal subscale Raw Score 
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Figure 3.4 - Boxplots to show differences between dementia and no dementia groups – ACTB tasks 
 
ACTB tasks - Prefrontal tasks 
IED stages completed IED errors block 1 
Modified dots task  2nd stage 
(frogs) 
Modified dots task 3rd stage 
(combined) 
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Figure 3.4 continued - Boxplots to show differences between dementia and no dementia groups – ACTB tasks 
ACTB tasks – Hippocampal tasks 
CANTAB PAL stages completed CANTAB PAL first trial memory score 
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Figure 3.4 continued - Boxplots to show differences between dementia and no dementia groups – ACTB tasks 
ACTB tasks – Cerebellar tasks 
CANTAB SRT median latency Finger sequencing task NEPSY train and car NEPSY car and motorbike 
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Figure 3.5 - Boxplots to show differences between dementia and no dementia groups – Table top tasks 
 
Table top tasks – Prefrontal tasks 
Verbal fluency  raw score Verbal fluency adjusted Tower of London stages 
completed 
Tower of London points 
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Figure 3.5 continued - Boxplots to show differences between dementia and no dementia groups – Table top tasks 
Table top tasks – Hippocampal tasks 
NAID Object memory NAID Memory for sentences 
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Figure 3.5 continued - Boxplots to show differences between dementia and no dementia groups – Table top tasks 
Table top tasks – Cerebellar tasks 
Finger-Nose Gait assessment 
  
94 
3.5 Differences between dementia and no dementia groups 
In my primary analyses, I assessed whether the ACTB CANTAB PAL was 
able to detect differences between people with Down’s syndrome who have 
early stage dementia and those who do not. 
I examined two different outcome measures from the CANTAB PAL. These 
were PAL first trial memory score, and PAL stages completed. The PAL first 
trial memory score gives the number of patterns correctly identified at the 
participant’s first trial or attempt. This is the outcome measure reported in the 
ACTB study and is the outcome measure I based my power calculation on. 
However, I also examined PAL stages completed, which refers to the number 
of stages which were completed by the participant; this had a better spread 
of data in my study sample, due to the lower number of participants 
performing at floor level.  
In my secondary analyses, I examined whether there were any significant 
differences between the two groups in any of the other ACTB cognitive tests 
and in the table top tests. The results, as well as further data on distribution 
are shown in Tables 3.7, 3.8 and 3.9.  
See Appendix tables A2, 3 and 4 for further detail on floor and ceiling levels 
according to level of intellectual disability. 
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Table 3.7 - Table showing differences in cognitive tests between dementia and no dementia groups – K-BIT II scores 
 
 Dementia No Dementia   
 n Mean   
(SD) 
Median 
(Range) 
Number 
at floor  
Number 
at 
ceiling  
N Mean   
(SD) 
Median 
(Range) 
Number 
at floor  
Number 
at 
ceiling  
Median 
difference 
(95% CI) 
P value c 
K-BIT II 
total raw 
score 
19 9.74 
(11.06) 
6             
(1-49) 
0  
(0.0%) 
0  
(0.0%) 
31 22.61 
(19.42) 
14       
(3-63) 
0  
(0.0%) 
0  
(0.0%) 
-6                 
(-20 to -2) 
0.006 
K-BIT II 
verbal 
subscale  
19 6.53    
(7.61) 
4             
(0-34) 
1  
(5.3%) 
0  
(0.0%) 
31 16.03 
(13.23) 
10           
(1-47) 
0  
(0.0%) 
0  
(0.0%) 
-6                 
(-12 to -2) 
0.002 
K-BIT II 
non verbal 
subscale  
19 3.21    
(4.16) 
2              
(0-15) 
4 
(21.1%) 
0  
(0.0%) 
31 6.58    
(6.91) 
3             
(0-20) 
6 
(19.4%) 
0  
(0.0%) 
-1                 
(-6 to 0) 
0.253 
 c
 Independent samples Mann Whitney U test 
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Table 3.8 - Table showing differences in cognitive tests between dementia and no dementia groups – ACTB tests 
 Dementia No Dementia   
 n Mean   
(SD) 
Median 
(Range) 
Number 
at floor  
Number 
at ceiling  
n Mean   
(SD) 
Median 
(Range) 
Number 
at floor  
Number 
at ceiling  
Median 
difference 
(95% CI) 
P 
value
 c
 
CANTAB PAL first trial 
memory score 
15 0.93  
(1.16) 
1                 
(0-4) 
7 
(46.7%) 
0    
(0.0%) 
30 2.87 
(3.75) 
1             
(0-15) 
10 
(33.3%) 
0     
(0.0%) 
-1                    
(-2 to 0) 
0.131 
CANTAB PAL stages 
completed 
15 1.40 
(1.12) 
2                 
(0-4) 
4 
(26.7%) 
0      
(0.0%) 
30 3.13 
(2.39) 
2             
(0-8) 
2    
(6.7%) 
2      
(6.7%) 
-1                     
(-2 to 0) 
0.016 
CANTAB IED stages 
completed 
15 0.60 
(0.83) 
0                 
(0-2) 
9 
(60.0%) 
0       
(0.0%) 
30 2.33 
(3.09) 
0.50        
(0-8) 
15 
(50.0%) 
0    
(0.0%) 
0                      
(-2 to 0) 
0.194 
IED errors block 1 15 16.5   
(10.7) 
19               
(0-32) 
n/a 2     
(13.3%) 
30 13.73 
(11.70) 
13.5        
(0-30) 
n/a 4 (13.3%) 3                       
(-3 to 9) 
0.514 
Modified dots task 2
nd
 
stage 
11 0.36    
(0.16) 
0.33        
(0.00 – 
0.58) 
10 
(90.9%) 
0     
(0.0%) 
22 0.45   
(0.34) 
0.33   
(0.08-
1.00) 
15 
(68.2%) 
4   
(18.2%) 
0                       
(-0.333 to 
0.167 
0.925 
Modified dots task 3
rd
 
stage 
11 0.32 
(0.14) 
0.36       
(0.12-
0.52) 
10 
(90.9%) 
0      
(0.0%) 
22 0.42   
(0.18) 
0.42   
(0.03-
0.91) 
16 
(72.7%) 
0    
(0.0%) 
-0.09                   
(-0.21 to 
0.03) 
0.133 
CANTAB SRT median 
latency 
17 1556.5 
(559.8) 
1626.0    
(640-
2350) 
n/a n/a 28 1172.6 
(609.6) 
1020.0 
(351-
2408) 
n/a n/a 404.5            
(35.5 to 
763.5) 
0.039 
Finger sequencing task 14 1.50 
(1.02) 
1                 
(0-4) 
1   
(7.1%) 
1    
(7.1%) 
29 1.83    
(1.04) 
2             
(1-4) 
0    
(0.0%) 
4  
(13.8%) 
0                         
(-1 to 0) 
0.275
NEPSY visuomotor 
precision train and car 
10 8.50   
(4.65) 
10               
(1-14) 
0  
(0.0%) 
0     
(0.0%) 
26 10.69 
(6.52) 
11           
(1-21) 
0     
(0.0%) 
0    
(0.0%) 
-2                     
(-7 to 2) 
0.393 
NEPSY visuomotor 
precision car and 
motorbike 
10 3.20    
(1.99) 
3                
(1-8) 
0  
(0.0%) 
0    
(0.0%) 
24 9.46 
(8.51) 
5             
(0-28) 
1    
(4.2%) 
0    
(0.0%) 
-2                      
(-10 to 0) 
0.028 
c
 Independent samples Mann Whitney U test 
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Table 3.9 - Table showing differences in cognitive tests between dementia and no dementia groups – Table top tests 
 Dementia No Dementia   
 n Mean   
(SD) 
Median 
(Range) 
Number 
at floor  
Number 
at 
ceiling  
n Mean   
(SD) 
Median 
(Range) 
Number 
at floor  
Number 
at 
ceiling  
Median 
difference 
(95% CI) 
P value
 
c
 
Verbal fluency raw score 14 2.93    
(2.70) 
3                 
(0-9) 
4 
(28.6%) 
n/a 30 6.10   
(4.19) 
6              
(0-17) 
3 
(10.0%) 
n/a -3            
(-5 to -1) 
0.010 
Verbal fluency adjusted 14 0.93    
(0.73) 
1                   
(0-2) 
4 
(28.6%) 
n/a 30 1.73    
(0.91) 
2             
(0-4) 
3 
(10.0%) 
n/a -1              
(-1 to 0) 
0.005 
Tower of London stages 
completed 
16 1.56   
(1.26) 
2                      
(0-3) 
5 
(31.3%) 
0    
(0.0%) 
27 2.30   
(1.17) 
2             
(0-4) 
1   
(3.7%) 
6 
(22.2%) 
-1             
(-2 to 0) 
0.106 
Tower of London points 11 3.27   
(2.49) 
3                   
(0-7) 
7 
(43.8%) 
0  
(0.0%) 
26 3.81    
(3.27) 
2.50        
(0-10) 
7 
(25.9%) 
2   
(7.4%) 
0                
(-2 to 2) 
0.756 
Object memory 12 3.50   
(2.94) 
3.50               
(0-9) 
7 
(43.8%) 
0  
(0.0%) 
22 6.41        
(2.40) 
6.50         
(1-10) 
5 
(14.8%) 
2   
(7.4%) 
-3              
(-5 to -1) 
0.007 
Memory for sentences 14 9.71    
(6.37) 
11                  
(0-21) 
3       
(18.8%) 
0  
(0.0%) 
29 14.31 
(12.14) 
10             
(1-44) 
1    
(3.3%) 
0   
(0.0%) 
-2               
(-9 to 3) 
0.406 
Finger-nose 14 4.93    
(2.92) 
4.50            
(1-10) 
0    
(0.0%) 
n/a 27 7.04   
(4.53) 
6.0               
(2-19) 
0  
(0.0%) 
n/a -1               
(-4 to 1) 
0.185 
Gait assessment 12 15.76 
(4.26) 
14.55     
(7.82-23.17) 
3      
(20%) 
n/a 26 14.08 
(5.19) 
11.96 
(6.53-
25.93) 
0  
(0.0%) 
n/a 2.345         
(-1.885 to 
4.74) 
0.155 
c
 Independent samples Mann Whitney U test 
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The CANTAB PAL is not able to detect differences between people with 
Down’s syndrome who have early stage dementia and those who do not 
have dementia, as the median values for both outcome measures are the 
same and the 95% confidence intervals for the median difference include 
zero. 
However, the 95% confidence intervals between the dementia and no 
dementia groups did not include zero in the K-BIT total raw score and K-BIT 
verbal subscale, CANTAB SRT median latency, Verbal fluency raw score 
and Object memory.  
I also examined whether there were any differences between the two groups 
in the CANTAB SRT total correct trials, which can be used as a measure of 
attention. The mean was 56.93 (SD 32.79) and the median was 59 (range 0-
100). There was no significant difference in the Independent samples Mann 
Whitney U test between the dementia and no dementia groups (p value 
0.185, median difference 12 (95% confidence intervals -36 to 8)). 
I examined whether there were any differences between the dementia and no 
dementia groups when using the carer rated assessments. As scores from 
these tests were also not normally distributed, I used non-parametric 
statistical tests. Table 3.10 shows these results. 
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Table 3.10 - Table showing differences in cognitive tests between 
dementia and no dementia groups – Carer rated assessments 
 Dementia No Dementia   
 N Mean 
(SD) 
Median 
(Range) 
n Mean 
(SD) 
Median 
(Range) 
Median 
difference 
(95% CI) 
P value
c
 
BRIEF: 
 
Shift 11 17.09 
(4.21) 
16.00 
(9-24) 
23 15.96 
(4.30) 
17.00 
(8-22) 
1 
(-2 to 4) 
0.445 
Inhibit 12 16.92 
(3.78) 
17.50 
(11-22) 
23 15.48 
(3.96) 
15.00 
(10-24) 
1.5 
(-2 to 5) 
0.344 
Working 
memory 
12 22.75 
(5.31) 
20.50 
(15-31) 
23 20.13 
(5.23) 
21.00 
(10-30) 
3 
(-1 to 7) 
0.310 
BRI  11 53.73 
(10.33) 
56.00 
(36-66) 
23 48.39 
(10.86) 
51.00 
(28-64) 
5             
(-2 to 12) 
0.176 
DLD: 
 
Short 
Term 
Memory 
(STM) 
19 8.47 
(4.01) 
10.00 
(0-13) 
31 3.00 
(3.51) 
2.00   
(0-13) 
6 
(3 to 9) 
<0.001* 
Sum 
Cognitive 
Scores 
19 26.47 
(8.90) 
26.00 
(7-38) 
31 13.23 
(10.68) 
14.00 
(1-37) 
15               
(8 to 20) 
<0.001* 
Total 
Score 
19 46.53 
(17.35) 
43.00 
(14-74) 
31 26.06 
(15.80) 
26.00 
(2-62) 
22 
(9 to 31) 
<0.001* 
c
 Independent samples Mann Whitney U test 
*Significant at the 0.05 level 
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3.5.1 Regression models 
In order to determine whether significant differences remained after 
accounting for age and gender in the relevant ACTB and table top tests, I 
conducted appropriate statistical models on the cognitive tests that showed a 
significant difference between the dementia and no dementia groups. Due to 
the small sample size, I was not able to add any further variables into the 
model. 
The most appropriate statistical models to use were discussed with a 
statistician (KR).  
Table 3.11 - Table showing differences between dementia and no 
dementia groups in cognitive tests when accounting for age and gender 
Measure N Model Estimate 
used 
Estimate 
(95% CI) 
P 
value 
CANTAB SRT 
median 
latency 
45 Linear 
regression 
Coefficient 391.083       
(-13.838 to 
796.005) 
0.058 
Verbal 
Fluency raw 
score 
44 Negative 
Binomial 
IRR 0.495     
(0.272 to 
0.901) 
0.021* 
NAID Object 
memory 
34 Negative 
Binomial 
IRR 0.571    
(0.393 to 
0.829) 
0.003* 
*Significant at the 0.05 level 
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3.6 Concurrent validity 
In order to assess concurrent validity, I looked at the strength of correlations 
between measures that assessed the same or similar areas of cognition. I 
compared the prefrontal, hippocampal and cerebellar tasks from the ACTB 
with measures from the table top tests and carer ratings which examined the 
same cognitive domain. These are shown in Tables 3.12, 3.13 and 3.14.  
As the data was not normally distributed, correlations were calculated using 
Spearman’s rank.  
Data from those at floor and ceiling is included for all measures, apart from 
Object memory and Memory for sentences, Tower of London points and Gait 
assessment where those who did not pass the teaching stage (or, in the case 
of Gait assessment, those who were not able to mobilise without assistance) 
are not included in the analysis. 
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 Table 3.12 - Correlation - Prefrontal measures 
Measure 
CANTAB IED 
stages 
completed 
(p) 
CANTAB IED 
errors block 
1 (p) 
Modified 
dots task 2nd 
stage (p) 
Modified 
dots task 3rd 
stage (p) 
Verbal 
fluency  
adjusted (p) 
Tower of 
London 
stages 
completed 
(p) 
CANTAB IED stages 
completed (p) 
 
-0.831 
(<0.001*) 
0.359 
(0.040*) 
0.458 
(0.007*) 
0.422 
(0.004*) 
0.443 
(0.004*) 
CANTAB IED errors block 1 (p) 
  
-0.265  
(0.136) 
-0.317  
(0.073) 
-0.314 
(0.038*) 
-0.435 
(0.004*) 
Modified dots task 2nd stage 
(p) 
   
0.773 
(<0.001*) 
0.464 
(0.007*) 
0.629 
(<0.001*) 
Modified dots task 3rd stage (p) 
    
0.562 
(0.001*) 
0.585 
(0.001*) 
Verbal fluency adjusted (p) 
     
0.479   
(0.002) 
BRIEF – Shift (p) -0.050  
(0.785) 
-0.052  
(0.779) 
0.014   
(0.949) 
-0.186  
(0.408) 
-0.074  
(0.689) 
-0.205  
(0.268) 
BRIEF – Inhibit (p) -0.336  
(0.056) 
0.366 
(0.036*) 
-0.133   
(0.545) 
-0.287  
(0.184) 
-0.160  
(0.374) 
-0.535 
(0.002*) 
BRIEF – Working memory (p) -0.443 
(0.010*) 
0.371 
(0.034*) 
-0.199  
(0.364) 
-0.220  
(0.312) 
-0.575 
(<0.001*) 
-0.574 
(0.001*) 
BRIEF –– BRI (p) -0.254  
(0.160) 
0.254   
(0.160) 
-0.118  
(0.601) 
-0.302  
(0.172) 
-0.181  
(0.323) 
-0.551 
(0.001*) 
*Significant at the 0.05 level 
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Table 3.13 - Correlation - Hippocampal measures 
Measure 
CANTAB 
PAL stages 
completed 
(p) 
CANTAB 
PAL first 
trial 
memory 
score (p) 
Object 
memory (p) 
Memory for 
sentences 
(p) 
CANTAB 
PAL stages 
completed 
(p) 
 
0.860 
(<0.001*) 
0.354 
(0.043*) 
0.048 
(0.761) 
CANTAB 
PAL first 
trial 
memory 
score (p) 
  
0.345 
(0.049*) 
0.010 
(0.952) 
Object 
memory 
   
0.204 
(0.254) 
DLD – STM 
(p) 
-0.467 
(0.001*) 
-0.502 
(<0.001*) 
-0.572 
(<0.001*) 
-0.250 
(0.107) 
DLD – Sum 
cognitive 
scores (p) 
-0.541 
(<0.001*) 
 
-0.574 
(<0.001*) 
-0.514 
(0.002*) 
-0.292 
(0.057) 
DLD – Total 
Score (p) 
-0.468 
(0.001*) 
-0.532 
(<0.001*) 
-0.565 
(<0.001*) 
-0.225 
(0.147) 
 *Significant at the 0.05 level 
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Table 3.14 - Correlation - Cerebellar measures 
Measure 
CANTAB 
SRT  
median 
latency   
(p) 
NEPSY 
visuomotor 
precision 
train and 
car          
(p) 
NEPSY 
visuomotor 
precision – 
car and 
motorbike 
(p) 
Finger 
sequencing 
task         
(p) 
Gait 
assessment      
(p) 
CANTAB 
SRT median 
latency (p) 
 
-0.408 
(0.013*) 
-0.258 
(0.141) 
-0.496 
(0.001*) 
 
NEPSY 
visuomotor 
precision 
train and 
car(p) 
  
0.750 
(<0.001**) 
0.563 
(<0.001*) 
 
NEPSY 
visuomotor 
precision 
car and 
motorbike 
(p) 
   
0.489 
(0.004*) 
 
Finger-nose 
(p) 
-0.479 
(0.002*) 
0.539 
(0.001*) 
0.465 
(0.006*) 
0.441 
(0.005*) 
-0.558 
(<0.001*) 
Gait 
assessment 
(p) 
0.382 
(0.021*) 
-0.442 
(0.010*) 
0.456 
(0.009*) 
-0.296 
(0.076) 
 
 
In general, there was correlation between some of the ACTB tests and the 
table top tests. There was significant correlation of mild to moderate strength 
between the ACTB tests and the tabletop tests that measured pre-frontal 
skills and cerebellar function. There was a mild correlation between the 
ACTB test that assessed hippocampal function (CANTAB PAL) and the NAID 
Object memory task. Memory for sentences was not correlated with any of 
the hippocampal tasks. 
The ACTB tasks that assessed prefrontal function were not well correlated 
with BRIEF scores, apart from the working memory subscale. The Tower of 
London stages completed was much better correlated with BRIEF scores, 
*Significant at the 0.05 level 
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although this was only a moderate correlation. All hippocampal measures, 
apart from memory for sentences were significantly moderately correlated 
with the DLD scores. 
In general, the ACTB has mild to moderate concurrent validity when 
compared to table top tests and carer ratings that assessed the same 
domains, although this varies according to brain region and on a test by test 
basis. 
3.7 Summary 
50 participants with Down’s syndrome were recruited. Of these, 19 had a 
diagnosis of dementia or possible dementia. Significant differences in age 
and abdominal circumference were found between the dementia and no 
dementia groups. Data on feasibility and psychometric properties of the 
ACTB and table top tests were calculated. The floor and ceiling effects vary 
from test to test, although the CANTAB IED stages completed and Modified 
dots task have a very large number of participants at floor.   
There were significant differences between the dementia and no dementia 
groups in scores from the CANTAB SRT median latency, Verbal fluency raw 
scores and Object memory. Significant differences in CANTAB SRT median 
latency score did not remain when accounting for age and gender. In 
general, the ACTB has mild to moderate concurrent validity when compared 
to table top tests and carer ratings that assessed the same domains, 
although this varies according to brain region and on a test by test basis. 
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Chapter 4. Discussion 
4.1 Overview 
In this chapter, I will summarise my results and comment on them. I will then 
discuss my findings in the context of other research before commenting on 
the strengths and limitations of this study. I will go on to discuss the 
implications of my findings, including my recommendations for what cognitive 
tests would be useful in an assessment battery for older adults with Down’s 
syndrome. I will conclude by commenting on areas for further research in the 
field. 
4.2 Summary of results 
This study assessed the Arizona Cognitive Test Battery (ACTB) against table 
top tests and carer rated assessments in 50 participants with Down’s 
syndrome. Most participants were able to attempt most of the tasks (between 
82% and 90% were able to attempt the ACTB tasks and between 68% and 
88% were able to attempt the table top tasks).  
Some of the tasks had acceptable numbers of participants that did not fall at 
the floor or ceiling level. Tests where less than 15% of participants were at 
floor or ceiling level included the K-BIT total raw score and verbal subscale, 
CANTAB PAL stages completed, CANTAB SRT, Finger sequencing task, 
NEPSY visuomotor precision, Tower of London stages completed, Memory 
for sentences, Finger-nose and Gait assessment. However, some of the 
tasks had a very high proportion of participants at floor, particularly the 
CANTAB IED stages completed (53% at floor) and the Modified dots task 
(76% to 79% at floor). 
95% confidence intervals for the median difference between the dementia 
and no dementia groups did not include zero in only three of the cognitive 
tasks. These were CANTAB SRT median latency, Verbal fluency raw score 
and Object memory. When accounting for gender and age, statistically 
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significant differences remained in Object memory and Verbal fluency raw 
score. CANTAB SRT median latency approached significance but was no 
longer significant at the 0.05 level. 
The ACTB tests were generally mild to moderately correlated with some of 
the table top and carer rated tests that assessed similar domains. There was 
significant correlation of mild to moderate strength between the ACTB tests 
and the tabletop tests that measured prefrontal skills and cerebellar function 
(a magnitude of between 0.314 and 0.629 for the prefrontal tasks and, where 
significant, between 0.382 and 0.539 for the cerebellar tasks). There was a 
mild correlation between the ACTB test that assessed hippocampal function 
(CANTAB PAL) and the NAID Object memory task (0.345 to 0.354). Memory 
for sentences was not correlated with any of the other hippocampal tasks. 
The ACTB tasks that assessed prefrontal function were not well correlated 
with BRIEF scores, apart from the working memory subscale. All 
hippocampal measures, apart from Memory for sentences were significantly 
moderately negatively correlated with the DLD scores (with a magnitude from 
0.467 to 0.574). 
4.3 Interpretation of results  
4.3.1 Demographics 
The sample included slightly more men than women and more participants 
with moderate/severe intellectual disability than mild intellectual disability 
(63% with moderate/severe intellectual disability compared to 37% with mild 
intellectual disability), although level of intellectual disability was not recorded 
for all the participants. 28% of the sample were living with family or friends 
and another 14% in an adult placement, which is very similar to a home 
environment. The remainder were living in supported accommodation. This 
reflects the fact that the sample was a community based sample and 
included participants with a range of level of intellectual disability. There were 
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no significant differences in gender, ethnic origin or type of accommodation 
between the dementia and non dementia groups. 
This study included a higher proportion of men compared to women in the 
dementia group (63.2% compared to 36.8%), which differs from what has 
been seen in a previous study, where more women than men were found to 
present with cognitive deterioration, although, like in my study, this was not 
found to be a statistically significant difference (Oliver et al, 1998).  
4.3.1.1 Age of study sample 
There was a significant difference in age between the dementia and no 
dementia groups. This is to be expected, as it is well known that increasing 
age is associated with increasing risk of dementia in the general population 
(Ballard et al, 2011), and in those with Down’s syndrome (Oliver et al, 1998). 
4.3.1.2 Generation of study sample 
It is important to consider historical context when comparing current research 
with older adults with Down’s syndrome to research with children, teenagers 
and younger adults with Down’s syndrome – not only are there differences in 
presentation related to age, but there are marked differences in education 
and health care that these population groups will have received. Alongside 
this, the skills that society is now promoting are changing. Nowadays, the 
ability to use computers and the internet and to be able to navigate through 
an increasingly digital age is, perhaps, starting to be viewed as more 
important and desirable than the fine motor skills that were required for 
industry half a century or so ago. 
This may therefore influence both formal and informal education and training, 
with younger generations receiving more training in computer based skills, 
possibly making them more likely to perform better in computer based 
assessments. 
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4.3.1.3 Recruitment 
As can be seen in Figure 3.2, there were unequal proportions of people with 
and without dementia recruited from each geographical area, with some 
areas not recruiting any participants with dementia and others recruiting more 
participants with dementia than participants without dementia.  
This may be due to differences in how participants were recruited in these 
localities. Participants with dementia were more likely to have been recruited 
through psychiatrists, whereas those without dementia may be more likely to 
have been recruited through day centres. This also highlights differences in 
local working arrangements and social care, as some areas may have been 
more likely to move people with higher needs out of the area whereas other 
teams may have been able to support them within the local area. Alongside 
this, local clinical policies and practice may mean that some teams are more 
likely to discharge patients with Down’s syndrome who do not have any 
active health concerns and others may not.  
4.3.1.4 Physical health 
Physical health problems were prevalent in the total sample, with 41% of 
participants having a thyroid problem and 18% having epilepsy. As dementia 
of Alzheimer’s type in Down’s syndrome is associated with epilepsy, it is not 
surprising that the percentage of people with dementia who had epilepsy was 
higher than those who did not have dementia (26% versus 13%), although 
this difference did not reach statistical significance.  
Interestingly, there were fewer people in the dementia group who had a 
family history of dementia as compared to the no dementia group, although 
this was not a statistically significant difference. Data on family history were 
only available from 33 participants and it may be that paid carers were not 
always fully aware of detailed family history when answering this question. 
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Average (median) pulse and diastolic blood pressure in the whole group was 
lower than the general population. This is a well known feature of Down’s 
syndrome, and, interestingly, low blood pressure has previously been 
suggested as a possible link to Alzheimer’s disease in people with Down’s 
syndrome (Morrison et al, 1996). 
There was a statistically significant difference in abdominal circumference 
between the two groups, with those with dementia having a smaller 
abdominal girth. The median weight for the dementia group was 64.9kg and 
in the no dementia group it was 82.6kg. There was no statistically significant 
difference in weight between the two groups, however the sample size for 
this variable was small (n=25). In the general population, midlife obesity has 
been found to be a risk factor for Alzheimer’s disease (Ballard et al, 2011), 
although as the course of dementia progresses, people with dementia are 
more likely to develop feeding difficulties and subsequent weight loss. 
4.3.1.5 Mental health 
Mental health problems were prevalent in this study, with 15.2% of 
participants having a history of psychosis and 32.6% of participants having a 
history of depression. There were higher percentages of people with 
psychosis and depression in the no dementia compared to the dementia 
group, although this was not a statistically significant difference.  
These rates are much higher than epidemiological studies predict, although a 
recent Scottish study identified a higher prevalence of mental ill health in 
adults with Down’s syndrome aged 45 and over compared to those aged 16-
44 (31.2% compared with 18.3%) (Mantry et al, 2008). The higher rates of 
mental illness in my study sample may be due to higher rates of mental 
illness seen in older people with Down’s syndrome (perhaps related to a 
reflection of behavioural changes seen in pre-clinical dementia). Alternatively, 
it may be explained by the fact that the majority of recruitment was through 
intellectual disability teams, and often through intellectual disability 
psychiatrists. It is likely that intellectual disability psychiatrists discharge 
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patients who do not have mental illness and are therefore more likely to 
recruit either people with dementia or those with other mental illnesses, such 
as psychosis or depression.  
Interestingly, there was also no significant difference between the dementia 
and no dementia groups when comparing possible organic condition as 
identified by the PAS-ADD checklist. This may be because of the small 
sample size in this group, as 22.2% of participants with dementia scored 
above the threshold for possible organic condition as opposed to 12.9% in 
the no dementia group. Alternatively, it may be because the PAS-ADD 
checklist asks about symptoms in the previous 4 weeks, so if symptoms of 
dementia were present but had not progressed over the previous 4 weeks, 
they are unlikely to have been detected using the PAS-ADD checklist. 
Furthermore, the PAS-ADD checklist is a screening tool rather than a 
diagnostic tool and only includes 6 questions related to symptoms of organic 
disorders, which may not be sensitive enough to detect a significant 
difference.  
4.3.1.6 Generalisability of study sample 
This study sample can therefore be said to be representative of a population 
of older adults with Down’s syndrome known to Intellectual Disability 
Psychiatry Services and living in a community setting in England. Given the 
age, location and methods of recruitment of the study sample, it is important 
to be cautious when comparing results to studies conducted with participants 
of a younger age, living in a different country or residential setting or recruited 
in a different way. The generalisability of this study could have been 
increased by recruiting from sites outside Greater London and the 
surrounding counties and using different recruitment channels (e.g. recruiting 
through charities and support groups as well as local Intellectual Disability 
Services). 
113 
4.3.2 Feasibility 
4.3.2.1 Number of participants attempting the tasks 
The majority of participants were able to attempt the majority of the tasks. A 
larger proportion of participants attempted the ACTB tasks as compared to 
the table top tasks and a larger proportion of the no dementia group were 
able to attempt the tasks as compared to the dementia group. 
The order of the tasks was counterbalanced to reduce position effects of the 
tasks; however, as the study was designed to assess the use of the ACTB, 
where participants were not keen to attempt all the tasks, I focussed on 
encouraging them to attempt the ACTB tasks. Alongside this, a number of 
the table top tasks were associated with teaching stages. If participants failed 
to pass the teaching stage, they did not continue with the task. The ACTB 
had a general training task – the CANTAB MOT, however, whilst a number of 
participants were able to pass the CANTAB MOT, this did not help teach or 
assess their abilities for each individual computer based task. These two 
reasons may go some way to explaining why slightly more participants were 
able to attempt the ACTB tasks compared to the table top tasks. Of course, 
another reason may be that the computer based tasks were more popular 
and/or easier to use.  
When considering feasibility, it is important to note that the assessment 
session took approximately 2-3 hours. Although breaks were given and, on 
occasion, second and third assessments were arranged, the requirements to 
concentrate and pay attention to the tasks were sometimes difficult for 
participants. It may be that participants did not have any previous experience 
with completing tasks in this manner before and some were likely to be 
unfamiliar with the concept of testing, with limited or no previous exposure to 
or schooling or examinations. 
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Therefore, attention and concentration levels and degree of exposure to 
previous cognitive testing were likely to have had an effect on whether the 
tasks were attempted.  
The CANTAB SRT total correct trials provided a measure of attention. There 
was no significant difference in this score when comparing the dementia and 
no dementia groups. However, this task may not have had satisfactory 
validity or been sensitive enough to detect differences in attention levels. It 
would be useful to consider adding a measure of attention into future 
cognitive test batteries as, subjectively, there appeared to be limited attention 
in a number of participants both with and without dementia. 
4.3.2.2 Choice of outcome measures 
Previous research using the ACTB in people with Down’s syndrome has 
reported the mean and standard deviation (SD) when reporting outcome 
measures (Edgin et al, 2010a). However, the data in this study did not fit a 
normal distribution, and much of the data was skewed. This is likely to be 
related to cognitive weaknesses in this group, resulting in large numbers of 
participants at floor for a number of outcome measures. I have therefore 
reported mean and standard deviation as well as median and range for the 
relevant outcome measures. 
Another consideration when comparing to previous research is that a number 
of different outcome measures are available for some of the cognitive tests, 
particularly the computer based tests, where, for example, in the case of the 
CANTAB PAL, up to 21 different outcome measures are available. Although 
this is designed to be a quality of these tests, when a large number of 
participants perform at floor, several of the outcome measures become 
invalid as they rely on participants completing some or all levels of the task. 
There is therefore a risk that non-valid measures are used, or that multiple 
statistical analyses are conducted using a variety of different outcome 
measures for the same test. When conducting my analyses, I selected a 
115 
limited number of outcome measures that were valid and applicable to my 
study sample, as described in Section 2.9.2. 
Three of the assessment tools are designed to be transformed to percentiles 
using population norms. These are the K-BIT II, NEPSY visuomotor 
perception and BRIEF scores. In the case of the NEPSY and BRIEF, the 
population norms are for children and therefore raw scores only were used in 
my analyses. In the case of the K-BIT, most of the participants in my sample 
would have been at the floor of the population norms (the floor for K-BIT II is 
an IQ of 40, and the K-BIT II appears to score lower than other popular 
psychometric tests for IQ). I have therefore used K-BIT II raw scores in my 
analysis, which had a good spread of measures in the study sample and 
reflects other research in the field (Edgin et al, 2010a).   
4.3.3 Difference between dementia and no dementia groups 
4.3.3.1 Floor and ceiling levels and distribution of data 
Tables 3.7, 3.8, 3.9 and Appendix tables A. 2, 3 and 4 show the floor and 
ceiling levels of the tasks and compare these in the dementia and no 
dementia groups. A number of tests had relatively acceptable floor and 
ceiling levels and a reasonable spread of results. These were K-BIT total raw 
score and verbal subscale, CANTAB PAL stages completed, CANTAB SRT, 
Finger sequencing task, NEPSY visuomotor precision, Tower of London 
stages completed, Memory for sentences, Finger-nose and Gait assessment.  
I used a fairly low threshold to determine floor and ceiling levels, however the 
original research on the ACTB was more stringent (Edgin et al, 2010a). 
A large proportion of participants both with and without dementia (37.8%) 
were at floor for the CANTAB first trial memory score, which was the 
outcome measure I based by power calculation on. Very large proportions of 
participants were at floor of the ACTB prefrontal tests (the CANTAB IED 
stages completed and the Modified dots tasks). 43.8% of people with 
dementia were at floor of the Tower of London points and for the Object 
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memory task, although these figures also included those who did not pass 
the teaching stage. 
When floor and ceiling levels are stratified according to dementia status and 
level of intellectual disability (see Appendix tables A2, 3 and 4) it can be seen 
that for some but not all cognitive tests, a higher proportion of those with 
dementia and moderate intellectual disability are at floor compared to those 
with dementia and mild learning disability. When interpreting these results, it 
is important to be aware that data on level of intellectual disability was 
missing for 15 participants and therefore n is only a maximum of 35. When n 
is low, small differences in real numbers can have a large influence on 
percentages, which may explain why for some outcome measures more 
participants with mild intellectual disability were at floor compared to those 
with moderate intellectual disability.  
4.3.3.2 Differences between dementia and no dementia groups 
Non parametric methods were considered in the absence of suitable 
transformations of the data. These are less sensitive to extreme values, but 
are also potentially less robust, as they rely on ranking of the data rather than 
the raw values of the data. Estimates (mean and median) and 95% 
confidence intervals are presented in order to indicate the magnitude of the 
difference. As this was an exploratory study, and analyses were not adjusted, 
significant p values should be interpreted with caution. 
95% confidence intervals for the median difference did not cross zero in only 
CANTAB SRT median latency, Verbal fluency raw score and Object memory. 
Of these, when accounting for gender and age, statistically significant 
differences were found in Object memory and Verbal fluency raw score. 
In this study, of the 12 cognitive tests that were evaluated, only 3 were found 
to detect differences between the dementia and no dementia groups and only 
one of these tests was from the Arizona Cognitive Test Battery. This is 
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unusual, as we would have expected more cognitive differences to be 
detected between the dementia and no dementia groups.  
Therefore, in answer to my hypotheses, the ACTB has not been shown to 
clearly detect differences between people with Down’s syndrome who have 
early stage dementia and those who do not have dementia. This study also 
did not identify many specific differences in the neuropsychological profiles of 
people with Down’s syndrome who have dementia and those who do not 
have dementia, with few tests identifying significant differences between the 
two groups. 
In general, therefore, we can say that either this study does not have enough 
power to determine differences between the dementia and no dementia 
groups in the majority of cognitive tests, or that the majority of tests used in 
this study do not pick up differences between the two groups.   
An alternative explanation may be that the no dementia group is, in fact, a 
group that is already in the process of developing a cognitive decline that has 
not yet been ascertained clinically. The similarities in the results of the 
cognitive tests may therefore reflect underlying similarities between the two 
groups. In fact, research with older adults with Down’s syndrome, has shown 
that early changes in personality and behaviour followed by an increase in 
frontal lobe characteristics and/or a deterioration in memory is seen prior to 
the development of full Alzheimer’s disease (Ball et al, 2006a).  
Based on these findings, I would therefore suggest that although it may be 
useful to use a cognitive test battery in older adults with Down’s syndrome 
when tracking changes over time, it may not be particularly useful for 
differentiating between those with and without dementia. In this case, it may 
be more helpful to focus on using specific tests that identify specific cognitive 
skills, although further research is required to confirm which cognitive skills 
deteriorate later in the course of dementia. 
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4.3.4 Concurrent validity 
4.3.4.1 Prefrontal function 
There was significant correlation of mild to moderate strength between the 
ACTB tests and the tabletop tests that measure prefrontal function. The 
ACTB tasks that assessed prefrontal function were not well correlated with 
BRIEF scores, apart from the working memory subscale. The Tower of 
London stages completed was much better correlated with more of the 
BRIEF subscales. This implies that the ACTB has mild to moderate 
concurrent validity with some of the other measures of prefrontal function, but 
that the Tower of London may have better concurrent validity, given that it 
correlates with both the ACTB tasks and the BRIEF. It is not clear, however, 
how valid the BRIEF is in this population, as it was designed for use in 
children and a number of cases were omitted from analysis due to 
incomplete datasets or high scores on negativity and inconsistency 
measures.   
4.3.4.2 Hippocampal function 
There was a significant mild correlation between the ACTB tests that 
assessed hippocampal function and the NAID Object memory task, but there 
was no significant correlation between Memory for sentences and any of the 
other hippocampal tasks. All hippocampal measures, apart from Memory for 
sentences, were moderately correlated with the DLD scores.  
Memory for sentences did not correlate with any other hippocampal tasks or 
carer rating scales, thus suggesting that either this is not a good test of 
hippocampal function, or that this utilises a different neural network. This is 
highlighted in the difference between verbal and visuospatial memory as 
described in section 1.4.6.1.1. 
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4.3.4.3 Cerebellar function 
The ACTB cerebellar tasks were mild to moderately correlated with the 
relevant table top tasks. Apart from the NEPSY visuomotor precision, these 
tasks mainly assessed cerebellar motor function rather than cerebellar 
cognitive function and until we have a better understanding of how to 
accurately measure cerebellar cognitive function, it is difficult to fully 
comment on how valid these tasks are in assessing cerebellar cognitive 
function. Nevertheless, some cerebellar tests appear to have good feasibility 
and are able to show differences between those with and without dementia.   
Regarding my secondary hypotheses, the ACTB has been shown to have 
mild to moderate concurrent validity when compared to table top tests and 
informant ratings, although this varies according to brain region and on a test 
by test basis. A number of tests had relatively acceptable floor and ceiling 
levels and a reasonable spread of results, however some had very high 
numbers of participants at floor. 
4.4 Results in the context of other research 
4.4.1 Cognitive function in children and adults with Down’s syndrome 
4.4.1.1 Executive function 
Similar to Pennington’s study comparing cognitive function in school aged 
individuals with Down’s syndrome to mental age matched controls 
(Pennington et al, 2003), I did not find differences in non verbal tests of 
executive function when comparing two groups (although Pennington’s study 
compared those with Down’s syndrome to mental age matched controls and 
in my study, I compared dementia and no dementia groups). The only 
executive function test that showed a difference between the two groups in 
my study was Verbal fluency, giving further credibility to Jarrold et al.’s 
comment that it may be that the modality in which information is recalled (i.e. 
verbal vs. non-verbal) moderates the results (Jarrold et al, 2008). It may be 
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that verbal measures of pre-frontal function better differentiate dementia from 
non-dementia cases than non-verbal tasks. 
However, the lack of significant differences between the groups may also be 
due to floor effects. The means of the Modified dots task were lower than the 
means of the same tests in the original ACTB paper, which is likely to be a 
reflection of the lower cognitive abilities of the sample in my study. This is 
confirmed by the lower mean K-BIT raw scores in my study compared to that 
in the ACTB paper. It may be that this lower cognitive ability is due to 
cognitive decline with age, although this study was not designed to address 
this question. 
4.4.1.2 Long term memory 
When comparing the CANTAB PAL first trial memory score results in my 
study to that in the original ACTB study, the mean was much lower in my 
study (2.22 compared to 7.42), which is likely to be a reflection of the 
differences in memory related to the difference in ages of people with Down’s 
syndrome in the two studies. The standard deviation and range were smaller 
in my study compared to the original ACTB paper, which may be a result of 
the more diverse range of ages and associated cognitive changes in the 
original ACTB paper (7-38 years, compared to 45-67 years). 
Notably, the spread of the results in my dataset were not normally distributed. 
Also, the percentage of participants at the floor of the CANTAB PAL first trial 
memory score was much higher in my study (37.8% versus 14.1%). 
4.4.1.3 Cerebellar function 
There are few studies of cerebellar cognitive function in people with Down’s 
syndrome. When comparing the distribution of the data of the CANTAB SRT 
median latency and NEPSY visuomotor precision train and car in my study to 
the original ACTB study, participants in my study showed poorer 
performance. This highlights what is already known about decline in fine 
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motor skills with age in Down’s syndrome. The original ACTB paper does not 
report NEPSY visuomotor precision scores for car and motorbike and reports 
a different outcome measure for Finger sequencing and I was therefore not 
able to compare them.  
As cerebellar cognitive skills are thought to include executive function and 
working memory, some of the tasks in the battery, particularly those that 
assess prefrontal functions, are also likely to assess cerebellar cognitive 
function. 
4.4.2 Cognitive function in adults with Down’s syndrome and dementia 
This study, like other studies with people with dementia of Alzheimer’s type 
and Down’s syndrome showed impairment of memory in people with 
dementia (Deb et al 2007a; Devenny et al, 2000). In my study, this was 
demonstrated by poorer performance in the Object memory task. Unlike 
Devenny’s study, my study was not able to show differences in cognitive 
decline with increasing severity of dementia as participants were not 
categorised according to level of severity of dementia. It is likely that the 
majority of my participants had mild dementia, given that those with more 
severe dementia would not have been able to attempt the tests and were 
therefore not recruited. 
In Ball et al’s study, which assessed 103 people with Down’s syndrome aged 
36-72 (including a group of 25 people with Dementia of Alzheimer’s type), 
significant differences were found between the dementia and no dementia 
groups on all 12 measures, using ANCOVA and taking into account age and 
level of intellectual disability (Ball et al, 2008). These included tests of 
executive function and memory, including Tower of London, Verbal fluency, 
Object memory and Memory for sentences. In my study, I also found a 
statistically significant difference comparing the dementia and no dementia 
groups on Object memory and Verbal fluency, but I did not identify significant 
differences in the Tower of London or Memory for sentences tasks.  
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A sub-set from the previous study who do not have a diagnosis of dementia 
of Alzheimer’s type are further described in Ball et al (2010) and the mean 
and range of the cognitive tests used are given. When comparing scores to 
my sample of participants in the no dementia group, the mean of Verbal 
fluency is very similar, the mean for Memory for sentences in my study is 
slightly lower and the mean for Object memory for my study is slightly higher.  
In her study, Ball identified behavioural disinhibition and apathy and in pre-
clinical dementia in people with Down’s syndrome (Ball et al, 2010). 
Alongside this, Adams and Oliver identified that participants with Down’s 
syndrome and cognitive deterioration showed decreases on measures of 
executive function and significant changes in behaviour even at the early 
stages of cognitive deterioration (Adams and Oliver, 2010). The sample 
group in my study is older, and those in the no dementia group may already 
have some of the changes in executive function and behaviour seen in the 
early stages of cognitive deterioration. This may explain why so many 
participants, including those in the no dementia group, performed at floor for 
a number of the executive function tests.  
Although this study was not designed to measure attention in older people 
with Down’s syndrome and dementia, it became evident during the course of 
data collection that a number of participants were not able to attempt or 
complete the tasks. At times this was due to limited attention. This seems to 
differ from cognitive testing in younger people with Down’s syndrome, where 
studies have been able to assess cognitive function over a similar 
assessment time and in more demanding situations, such as during MRI 
scanning or ERP testing. 
Although there were no statistically significant differences between the 
dementia and no dementia groups in the CANTAB SRT total correct trials 
(the outcome measure from the SRT which can be used as a measure of 
attention), the median score was 59 out of a possible total score of 124, 
which is fairly low for a task of relatively low cognitive demand. Das et al 
found that older adults with Down’s syndrome performed more poorly on 
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cognitive tasks, particularly those that required planning and attention when 
compared to older adults with intellectual disability not due to Down’s 
syndrome and younger adults with intellectual disability both with and without 
Down’s syndrome (Das et al, 1995). Krinksy-McHale et al (2008) have 
suggested the addition of a selective attention task (a paper and pencil 
picture cancellation task) to a neuropsychological battery for dementia in 
Down’s syndrome and have found that changes in performance can be 
observed approximately 2 years before a clinical diagnosis of dementia.  
Like the findings in Deb’s qualitative study (Deb et al, 2007a), in my study I 
also noticed that participants were generally slow. This is reflected in the long 
median latency times seen in the CANTAB SRT, and may also have 
contributed to slowness of initiation in other cognitive tasks. 
4.5 Strengths 
This is the first study to fully assess the use of the ACTB in older adults with 
Down’s syndrome and compare its use in those with dementia to those 
without dementia. The study was designed to be pragmatic so that results 
could be directly applied to this population. It used manualised standardised 
assessments of cognitive skills in 50 adults with Down’s syndrome. As the 
primary researcher, I was a trainee in the Psychiatry of Intellectual Disability 
and thus had experience working with people with intellectual disabilities, 
including in assessing capacity and making information accessible. I also 
attended training on use of the CANTAB and the ACTB. 
Dementia or possible dementia cases were clarified by consensus opinion, 
using medical information collected at assessment and from clinical teams.  
Statistical analyses were hypothesis based and limited to specific statistical 
tests that were relevant to the research question, thus reducing the possibility 
of multiple analyses and type I errors. Statistical analyses were conducted in 
consultation with an experienced medical statistician. 
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4.6 Limitations 
There are a number of limitations to this study, which mainly arise from the 
logistical issues of working with this demographic population. I will discuss 
them below. 
4.6.1 Sample size 
This study was initially powered to detect an effect size of 0.74, at 80% 
power and with a 5% overall significance level. This calculation was based on 
the mean and standard deviation of the CANTAB first trial memory score, 
which was taken from the original ACTB paper (Edgin et al, 2010a). 
The CANTAB PAL first trial memory score had a very different mean and SD 
in this study compared to that in Edgin’s study. It also had a large number 
(37.8%) of participants at floor and was therefore not the preferred outcome 
measure for use in this population. 
When interpreting the results, we therefore have to be aware of the possibility 
of this study being underpowered and the subsequent possibility of type II 
errors (i.e. false negatives). Although sample size is a limitation, it only 
relates to the analyses examining the differences between the two groups. 
Data on feasibility and concurrent validity of the tests should not be affected 
by the sample size. The sample size is comparable to several other studies 
of cognitive skills in this population group. 
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4.6.2 Confounding factors 
There are a number of confounding factors that may have influenced the 
results. 
In the general population, age and gender are known to be related to 
dementia. Where relevant, these were accounted for using statistical models. 
Level of intellectual disability is also likely to affect scores on cognitive tests. 
However, as I was not able to obtain a full data set for this variable, I was 
unable to account for this in the analyses, as this would have narrowed down 
the sample size even further. 
There are several other factors that may have influenced performance, 
including mental and physical health, sensory impairments and medication. I 
was not able to account for these in secondary analyses due to the small 
numbers in the study. However, in my initial analysis I did not find many 
significant differences in mental and physical health conditions when 
comparing the dementia and no dementia groups. 
Other factors such as the timing of assessments and location may have also 
possibly confounded results and it is important to consider this when 
interpreting the results. However, seeing most participants in a familiar 
environment is arguably a strength as it allowed them to perform at their best, 
free from the distractions of an unfamiliar environment. I tried to be as flexible 
as possible, allowing participants to stop and continue on another occasion if 
required, in order to ensure that each participant performed as well as they 
could.  
There may also be other hidden confounders or mediators that I am are not 
aware of or have not considered. 
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4.6.3 Dementia diagnosis 
Participants were categorised into either a “dementia” or “no dementia 
group”. This categorisation was done in consultation with treating clinicians 
and with my primary supervisor. In most cases, diagnosis (or lack of 
diagnosis) was clear cut, but in some cases, participants were said to have 
possible dementia. They were included in the dementia group.  
There continues to be a lack of clinical consensus in the diagnosis of 
dementia in people with Down’s syndrome and there is a chance that clinical 
dementia diagnosis was not consistent amongst the sample. However, it has 
been shown that a clinical diagnosis of dementia is just as reliable, if not 
more so, than manualised criteria (Sheehan, personal communication). 
There are also likely to be participants in the no dementia group who will 
move into the dementia group over time. It is therefore important to 
remember that the dementia/no dementia groups were used in order to 
answer the research question but are somewhat transient. It may be more 
useful to consider the no dementia group as a pre-clinical dementia group in 
this age group. 
4.6.4 Down’s syndrome diagnosis 
Participants were recruited through intellectual disability teams, care homes 
and day centres. Most people presented with classical facial features of 
Down’s syndrome, but features were more distinctive in some compared to 
others. Most participants and clinical teams did not have results of a genetic 
diagnosis available and therefore a diagnosis of Down’s syndrome was 
accepted if the researcher was told by the referring person (i.e. learning 
disability team, day centre or care home staff) that the participant had Down’s 
syndrome. 
Participants in this study therefore do not have genetic confirmation of 
Down’s syndrome and it is not possible to report on differences between 
those with a full trisomy and those with a translocation or mosaicism. 
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4.6.5 Assessment procedures 
The assessment was designed to be undertaken in one session if possible, 
with timing carefully considered so as to obtain as much useful and relevant 
information as possible to answer the research question and to avoid long 
and tiresome assessments for the participant and their carers or relatives.  
In some cases, the attention and concentration of participants was limited, 
which made carrying out the full assessment in accordance with the manual 
challenging. 
Participants’ attention may have fluctuated during the course of the 
assessment; some participants became more tired during the course of the 
assessment, although others settled in to the testing process and became 
more engaged as the assessments progressed. In order to account for 
position effects of the tests, the battery was counterbalanced after 26 
participants had been recruited.  
4.7 Implications of results 
This study shows that particular tests, be it from the ACTB, table top tests or 
carer ratings are feasible to use and have mild to moderate concurrent 
validity when used in older people with Down’s syndrome. A few of the tests 
showed differences between the dementia and no dementia groups. 
However, most tests did not detect differences between the two groups.  
These tests are likely to have some value when assessing cognitive skills in 
both research and clinical practice. When using these tools, researchers and 
clinicians need to be aware of possible confounding factors and take these 
into account when conducting the tests and when interpreting the results. 
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4.7.1 Type of test used 
Computer based, table top and carer rated tools can all be used to assess 
cognitive skills in older people with Down’s syndrome. They each have their 
advantages and disadvantages, which I will discuss below. If possible, it may 
be preferable to use all three methods in order to triangulate data. 
4.7.1.1 Computer based tests 
Computer based tests can generate a large amount of data from a relatively 
simple cognitive paradigm. As errors can be measured, an error rating can 
sometimes be used as an outcome measure to overcome the problem of 
high floor levels. 
The CANTAB tests in particular have been extensively used in a number of 
populations and are becoming increasingly used in people with Down’s 
syndrome. Training and specific hardware and software requirements make 
the tests well standardised and less likely to be modified, making them 
suitable for use at times when standardisation is very important, for example 
in clinical trials. Data is generated in a formatted spreadsheet, making 
subsequent analyses less onerous. 
However, the CANTAB tests have not specifically been designed for people 
with intellectual disability and the tests are often abstract and may not be that 
engaging for this population group. For example, the graphics are very basic 
compared to current computer games, the patterns are sometimes small and 
difficult to see (e.g. a blue pattern on a black background) and the sound 
effects are monotonal. 
The two other computer based tests used in this study – Modified dots task 
and Finger sequencing task – were developed by the Down Syndrome 
Research Group, University of Arizona. They were specifically designed to be 
engaging tasks for this population group and use cartoons and more colourful 
graphics and a more engaging variety of sounds. They have been validated, 
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but are not in common use and it remains to be seen whether they will 
continue to be used in this population group, as they may place more of a 
technical demand on the researcher. For example, a number of outcome 
measures from the Finger sequencing task require two researchers to assess 
(one to encourage the participant and one to count the number of valid finger 
taps), and even with two researchers it can be difficult to score.  
The tests included in the Arizona Cognitive Test Battery (ACTB) have been 
selected or designed for people with Down’s syndrome and therefore do not 
require verbal responses, thus limiting the load required for verbal memory 
and reducing this as a confounding factor.  
Researchers and clinicians need to be cautious of the wide variety of 
outcome measures generated by several of the computer based 
assessments, as some of them may not be valid or applicable if many 
participants do not complete all the levels. Some of the computer tests 
require the purchasing of specific hardware and software which can make 
research costs quite expensive and may rule out their use in the clinical 
setting. 
4.7.1.2 Table top tests 
These are easier to administer and some have been specifically developed 
for use with people with intellectual disability. They often only generate one 
or two outcome measures. Due to the nature of these tests, they can be 
easier to modify/adapt according to the needs of the participant although this 
also means that they are at more risk of being less standardised. In this 
respect, they might be more appropriate for use in clinical cognitive 
assessments. 
Most table top tests used in this study had minimal cost, although some, such 
as the Tower of London test have high initial costs, due to the purchase cost 
of the materials. 
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4.7.1.3 Carer rated assessments 
Carer rated assessments are easy to administer and score. They are 
therefore less time consuming than the computer based and table top 
cognitive tests. Some, such as the DLD, have been specifically developed for 
people with intellectual disability, and are already well used in research and 
clinical practice. 
They provide second hand information of cognitive functioning and the quality 
of information given depends on the quality of the relationship between the 
rater and the person with intellectual disability. 
The DLD is widely used in both research and clinical practice, and is easy for 
carers to complete and for researchers to score. The BRIEF has a number of 
statements that may not be applicable to people with intellectual disability 
(e.g. “does not check work for mistakes”) and is more time consuming for 
researchers to score.  
Carer rated assessments may be best used alongside participant based 
tasks. However, they may be a good substitute for participants who perform 
at floor for a number of cognitive tests. Response rates are likely to be 
higher. Applicable carer rated assessments such as the DLD are a valuable 
addition to cognitive testing, however further development regarding 
identifying subsections of the tools and whether they can assess specific 
cognitive skills are likely to provide more information to the researcher.  
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4.7.2 Recommendations for test battery  
The main aim of this study was to assess the use of the ACTB in older adults 
with Down’s syndrome and establish its validity in testing for dementia. 
However, as the ACTB is an assessment battery, there is potential for 
variation in the feasibility and validity of each individual task. Based on the 
findings of this study, I have made some suggestions regarding which of the 
tests in this battery are most useful when assessing cognitive skills in older 
people with Down’s syndrome. I suggest that a combination of computer 
based tests, table top tests and carer rated assessments are useful when 
assessing cognitive skills in this population. Together they have different 
strengths and limitations as described in the previous section and therefore a 
combination should hopefully allow to play to the strengths of each test while 
minimising the limitations. In Table 4.1 I have detailed the tests from this 
study that I would recommend are included in a cognitive test battery for 
older people with Down’s syndrome. 
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Table 4.1- Recommended cognitive tests to use in a cognitive test battery for 
older people with Down’s syndrome. 
Test Outcome measures Comments 
K-BIT II -Total raw score 
- Verbal subscale 
Able to detect differences 
between dementia and no 
dementia groups. Easy to 
administer. Used in other studies. 
CANTAB PAL - Stages completed Used in many similar studies 
CANTAB SRT - Median latency  
- Total correct trials  
Median latency assesses 
cerebellar function and is able to 
detect differences between 
dementia and no dementia 
groups. Total correct trials 
assesses attention 
Verbal fluency - Raw score Able to detect differences 
between dementia and no 
dementia groups. Easy to 
administer. Used in other studies. 
Tower of 
London 
- Stages succeeded 
on 
Easy to administer. Used in many 
other studies. 
NAID Object 
memory 
 Able to detect differences 
between dementia and no 
dementia groups. Easy to 
administer. Used in other studies. 
DLD - Sum of cognitive 
scores 
- Total score 
Able to detect differences 
between dementia and no 
dementia groups. Easy to 
administer. Used in many other 
studies. 
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4.8 Future research in the field 
4.8.1.1 This study  
This study feeds in to a larger study looking at individual differences in the 
cognitive profiles of people with Down’s syndrome, run by the LonDownS 
consortium (www.ucl.ac.uk/londowns/). The LonDownS consortium aims to 
further understand dementia in people with Down’s syndrome using a 
multidisciplinary approach.  
The size of the LonDownS study should overcome the problems with sample 
size that I encountered in my study. The greater numbers of participants that 
are planned to be recruited into the LonDownS consortium study should also 
allow for more variables to be controlled for in data analysis (in particular, 
level of intellectual disability and possibly level of severity of dementia). 
Genotyping from participants will help further understand genetic risk and 
protective factors for specific cognitive skills and deficits. Participants may 
also be invited to donate a few hair samples in order to grow stem cells, to 
understand underlying pathology on a cellular basis. 
It is hoped that some participants will also be able to participate in an EEG 
based ERP (Event Related Potential) study, which will allow for further 
understanding of the electrophysiological changes associated with cognition 
in this group. 
4.8.1.2 Other research 
Collaborative and interdisciplinary working is likely to further neuroscience 
research at a faster rate. Alongside looking at clinical cognitive assessments 
(which are valuable, but have limitations, as described previously), research 
examining how the brain is working during cognitive testing is also likely to be 
highly beneficial. 
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This includes neuroimaging studies (including MRI and PET), 
electroencephalography (including ERP based paradigms) as well as 
genetic, cellular and animal studies. 
Rather than thinking about cognitive deficits in terms of location (ie. 
prefrontal, hippocampal and cerebellar), it may be more useful to think about 
them in terms of specific skills (eg. working memory, visuo-spatial long term 
memory etc), as it is likely that more than one area of the brain is involved in 
each function. This is reflected in our understanding of neural networks, for 
example, visuo-temporal attention requires an intact cerebellum, suggesting 
that the cerebellum plays an important role in this neural network (Keren-
Happuch et al, 2012).  
There is a lack of research on cerebellar cognitive function in people with 
Down’s syndrome, including older adults with Down’s syndrome. It would be 
important for cognitive research, alongside functional imaging and animal 
studies to examine this. There is also more research required to understand 
attention and whether (and if so, how) this changes with age and/or dementia 
in people with Down’s syndrome. 
Whilst it is well established that people with Down’s syndrome have a much 
higher rate of dementia than those in the general population, it is still not 
clear why some people with Down’s syndrome will develop dementia and 
others do not appear to develop the clinical signs of dementia. We are aware 
of a few genetic risk factors, such as APO-E (Prasher et al, 2008) and 
PICALM, (Jones et al, 2013), but there is further work to be done regarding 
identifying risk and preventative factors. If we can further understand this 
question, it may go some way to helping our understanding of dementia in 
the general population. 
At present, there are a number of individuals, research groups and 
collaborations working on research in cognitive deficits in with Down’s 
syndrome, from mouse studies and cellular studies to clinical trials. The 
challenge to the research community is how to coordinate current and future 
135 
research so that findings are easily disseminated and translated to clinical 
practice.  
4.9 Conclusion 
Some tests in the ACTB test battery appear to be feasible and valid in older 
adults with Down’s syndrome, although they did not clearly identify 
differences between those with dementia and those without dementia. Table 
top tests have also been shown to be feasible and valid, although they vary 
on a test by test basis. Specific table top tests (such as Object memory) may 
be better at detecting differences between those with and without dementia, 
although it may be that there are few differences in specific cognitive skills 
between the two groups, and it may be more useful to consider older adults 
with Down’s syndrome without a diagnosis of dementia as a pre-clinical 
group. 
The assessment battery used in this study may be helpful in assessing 
cognitive skills and cognitive decline in older people with Down’s syndrome, 
however it may be of limited value in those who have a diagnosis of 
dementia. It would be helpful to include an assessment of attention in any 
cognitive battery used in older adults with Down’s syndrome.  
Research is moving away from a dementia/no dementia dichotomy and 
perhaps moving towards dementia as a final outcome on a continuum. 
Therefore, assessments of specific cognitive skills, perhaps using some of 
the assessment tools examined in this study may contribute to future 
research from epidemiological studies to clinical trials, as well as having a 
clinical application. 
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logo of service/ R&D Department 
 
Participant information sheet 
 
  
my name is Amanda Sinai 
  
I am doing some research 
 
Research is when we ask people questions and 
do tests to find out things 
  
 
I am writing to ask if you would like to help me 
 
 
 
To help you understand this letter you can 
 
 ask someone to read it for you 
 
 
 
 
 
 talk to your carer about it 
 
 
 
 
 
A study about how different parts of the brain work in 
older people with Down’s syndrome 
Insert 
picture of 
researcher 
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What is my work about?  
  
 
 
I am finding out about older people with 
Down’s syndrome 
 
 
  
 
 
 
 
 I want to find out how different parts of the 
brain work in older people with Down’s 
syndrome  
 
 
 
 
 I want to find out if this is different for 
people with Down’s syndrome and 
dementia  
 
 
 
 
 I want to find out if there are genetic 
reasons for this  
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Why do I want to see you? 
  
 
I want to talk to you  
 
 because you have Down’s syndrome  
 
 because you are 45 years old or older 
 
 
 
 
 
 The information you give can help to make 
things better for people with Down’s 
syndrome 
 
What will happen if you take part? 
  
If you agree to take part 
 
 I will ask you and your carer some 
questions 
 
 I will ask your care team some questions 
 
 
 
 your carer will fill in some forms 
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 you will do some tests – these are like 
games 
 
 
 
 
 some of the tests will be on a computer 
 
 
 
 
 
 I will check your blood pressure and 
general physical health 
 
 
 
 
 I will collect some of your spit (saliva) 
 
 
 
 I will give you a cup with a small sponge 
on a stick 
 I will ask you to put the sponge in your 
mouth  
 this is to soak up some of your spit 
(saliva) 
 
 Then we will put the sponge in the cup 
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 I will ask you to have a blood test  
 the blood test may hurt a little 
 
 
 
 It is OK if you do not want the blood test 
 
 
 
 
 
the meeting will last for about 2 or 3 hours 
 
 
 
 
 
 
we can meet at a place you know like your 
home 
 
 
 
 
 
your carer or worker will also come to the 
meeting 
 
 
 
 
 
 
2 - 3 hours 
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Do you have to take part? 
  
 
you can tell me Yes if you want to take part  
 
 
 
 
 
 
you can tell me No if you do not want to take 
part 
 
 
 
 
 
 
if you say no it will not change the care you get 
 
 
 
 
 
if you decide to take part, I will ask you to sign a 
consent form 
 
 
 
 
you can stop taking part at any time 
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What happens after you have seen me? 
  
 
 
If you tell me it’s OK I will 
   
 
 ask your doctor or care team about you 
 
 
 
 
 
 tell your doctor about the tests we did 
 
 
 
 
 
 
 tell your care team about the tests we did 
 
 
 
 
 
 
 send you a copy of your results 
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We will test your blood or spit in a laboratory  
 
 we may keep it in the laboratory for more 
tests 
 
 
 
 
 
 
 we may need to send it to another place 
so that they can look at it  
 
 
 
 
 we will take out your name if we send it 
away 
 
 
 
 
 
We will also put the test results on a computer 
 
 other people can then look at the 
information 
 
 
 
But they will not know it is about you – we will 
take out your name and where you live 
(personal information) before it goes on the 
computer 
 
 
name 
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I will give you a small gift or gift voucher to 
say thank you 
 
 
   
 
if you take part in my study 
 
 
 
 
 the information you give will be confidential  
 
 I will not talk to anyone else about you 
without asking you first 
 
 
 
 
 I will not use any information with your 
name and address 
 
 
 
 
But I would like to keep your name and address 
on a list  
 
 
This is so we can contact you if we need  
 
 more information 
 
 
 
name 
Your Name 
27 Your Street 
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 to do more research  
 
 
 
If you want to talk to me 
  
you can phone me 
 
 
or 
 
 
you can email me 
 
 
 
 
 if you would like to take part in the study  
 
 
 
 
 
 
 if you have any questions about the study 
 
 
 
 
 
 
 if you are unhappy about something 
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my phone number is 
 
020 76 79 90 33 
 
 
 
 
      my email address is 
 
a.sinai@ucl.ac.uk 
 
 
 
If you are unhappy about something, you can 
also talk to your local PALS team 
 
 
 
Their phone number is  
 
(insert local phone number) 
 
 
 
Thank you for looking at this 
 
This research project has been reviewed by the North Wales - West Research  
Ethics Committee, who are there to make sure you are treated well. 
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Carer/Consultee Information sheet 
      
Name of clinician 
Address 
 
 
My name is Amanda Sinai and I am a higher trainee in the Psychiatry of 
Learning Disability. I am carrying out research to examine the specific 
differences in cognitive functions (brain functions) between people with 
Down’s syndrome who have dementia and those who do not have dementia. 
The study is funded by the Baily Thomas Charitable Fund and sponsored by 
University College London, where I will be working towards an MD (Res). 
The study has been reviewed by the North Wales - West Ethics Committee. 
 
About the research project 
What is the importance of the study? 
People with Down’s syndrome are known to have higher rates of dementia. 
People with Down’s syndrome may also have changes in specific brain 
functions. For example, they might have specific problems with short term 
memory.  
An assessment to measure these brain functions has been developed for 
adults with Down’s syndrome. It is called the ACTB (Arizona Cognitive Test 
Battery). It has not been tested in older adults with Down’s syndrome and 
dementia. This is important because it would increase our understanding of 
specific brain functions and dementia in people with Down’s syndrome. It 
could later be used to improve assessment and management of people with 
Down’s syndrome and dementia.  
We plan to assess the ACTB in older adults with Down’s syndrome, including 
whether it can detect differences between people who have dementia and 
those who do not. 
We will ask participants to give a blood or saliva sample for genetic (DNA) 
analysis. This will be used to determine whether genetic factors might be 
related to changes in brain function in older people with Down’s syndrome 
who develop dementia. 
 
A study about how different areas of the brain work in 
older people with Down’s syndrome 
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Who is eligible? 
We are looking for people with Down’s syndrome, aged 45 and above. We 
are recruiting people both with and without a diagnosis of dementia. 
Participants will need to be able to understand simple verbal commands and 
perform simple puzzles and games. We will include people who have stable 
and treated mental or physical health problems. We will not be able to 
include people who have untreated thyroid problems or epilepsy, or active 
psychosis or mood disorders. We will not be able to include people who have 
had a previous stroke or a significant head injury. 
We will include people who lack capacity to consent to the study. If a 
participant lacks capacity, we have to seek an opinion from a personal 
or nominated consultee. 
 
What will the assessment involve? 
We will recruit participants with Down’s syndrome with and without dementia.  
Participants will take part in a 2 – 3 hour assessment which will involve them 
completing tests (like games) on a touchscreen computer tablet and using 
tabletop tools. Relatives or carers will be asked to present during the meeting 
and will be asked to complete informant questionnaires during this time. 
Participants will be given a break half way through the interview, or more as 
required.  
 
We will collect some basic information about the participants from them and 
their carers. We may also discuss participants with their community learning 
disability team and look at their patient records. 
We will check participants’ blood pressure and general physical health. We 
will also take a blood test or a saliva sample for genetic (DNA) and related 
biomarker analysis.  
The assessment will be arranged at a time and place that is convenient for 
the participants; this may include their home address or their local community 
learning disability team. 
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What happens after the assessment? 
We will send a summarised report of our findings to the participant, their care 
team and their GP. We will also provide a small gift or gift voucher to all 
participants as a way of saying thank you. 
Genetic analysis may be performed in laboratories outside University College 
London. Occasionally the analysis may have to be performed outside the UK 
in which case only fully anonymised samples will be released.  
If a participant who has not been diagnosed with dementia by the care team 
has a score suggestive of dementia on the cognitive assessment, we will let 
the care team know, who can then take the appropriate action. We do not 
think that genetic tests will reveal any findings that are important to the health 
of the participant. However, we will seek consent from the participants to 
contact their learning disability teams and/or GPs if we find known genetic 
problems that are important to their health (apart from those related to Down 
syndrome) so that they can be considered for referral to a clinical geneticist 
for further input. 
The results from the study, including the genetic results, will be stored on a 
database. These will be anonymised. The results may be sent to other 
researchers or shared with other researchers (these will be anonymised). 
All personal data will be handled in accordance with the Data Protection Act. 
Personal data will be securely held on the UCL IT system. Access will be 
restricted to the study Chief and Principle Investigators and their nominated 
researchers.  Personal data will be stored separately from the genetic and 
clinical database. Personal data will not be disclosed without the consent of 
the participant (or consultee if the participant does not have capacity to 
consent).  However, if there are vulnerable adult concerns, a keyworker or 
social worker may need to be informed and if there are health concerns, the 
participant’s care team or GP may need to be informed.  
Biological samples will be anonymised at the point of collection. The Chief 
and Principle Investigators will be the guardians of the anonymisation codes 
which will be held securely. 
Anonymised paper records will be stored securely within the Faculty of Brain 
Sciences at University College London. The anonymised genetic and clinical 
data will be entered into an electronic database held within the Faculty of 
Brain Sciences at University College London.  
Anonymised samples may be shared with other research groups who are 
conducting research in the field of learning disabilities. Samples may be 
stored for use in future research. 
Anonymised data may be shared with other research groups or entered onto 
publically accessible databases such as Decipher. This is standard practice 
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in genetic studies, and the best way to quickly share information about new 
genetic findings with other researchers and clinicians across the world.  
We would like to keep a record of participant’s contact details so that we can 
contact them if we need more information or if we are thinking about doing 
more research. 
 
What are the risks and benefits of the study? 
There are few risks to potential participants (except for possible frustration 
and anxiety when completing the tasks). Frustration and anxiety will be 
minimised by giving one planned break and having the option of further 
breaks if appropriate.  
Saliva sample collection may be slightly uncomfortable, but should not hurt. 
Risks of blood tests are known, and include mild pain, some bleeding and 
bruising. We can use a cream before the blood test to reduce pain.  If it is 
more convenient, we can arrange for the blood test to be taken at the same 
time that the participant is due to have routine blood tests. 
This study will benefit participants as it will provide baseline tests, against 
which future change can be measured. By increasing knowledge about 
people with Down’s syndrome and people with dementia, it may also benefit 
others in the future.  
A decision to withdraw at any time, or a decision not to take part, will not 
affect any aspects of care. 
 
Advice and complaints 
If you have any concern about any aspect of this study, you or someone you 
trust should ask to speak to Amanda Sinai or a member of your care team 
who will do their best to answer your questions. If you remain unhappy, you 
can contact your local PALS (Patient Advice and Liaison Service) team 
(insert local telephone number) or you can complain formally through the 
NHS Complaints Procedure (details can be obtained from your local PALS 
team).   
 
Please feel free to contact me if you have any questions. 
 
Thank you for taking the time to read this letter 
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Details of contact person 
My name:  Amanda Sinai 
Address:  Department of Mental Health Sciences, 
   University College London, 
   2nd Floor Charles Bell House, 
67-73 Riding House Street, 
London 
W1W 7EY 
 
E-mail address: a.sinai@ucl.ac.uk 
 
Telephone:   020 76 79 90 33  
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Consent form - participant 
 
Participant Identification Number:  
 
 
 
Please tick no      or yes      for each part 
  
  
I have read the information 
sheet about the research 
 
 
 
  
  
I can understand the 
information sheet  
 
 
  
  
I could ask questions if I 
wanted to 
 
 
 
  
 
 
 
A study about how different parts of the brain work in 
older people with Down’s syndrome 
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Please tick no      or yes      for each part 
  
  
I understand that it is my 
choice to take part in this 
study 
 
 
 
  
  
 
I understand that I can say 
no at any time if I want to 
stop 
 
 
 
 
  
  
 
I understand that it will not 
change the care I get 
 
  
  
you can ask my doctor or 
care team about me 
 
you can look at my doctor’s 
notes 
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Please tick no      or yes      for each part 
  
  
 
 
 
I agree to take part in this 
study 
 
 
 
 
 
 
 
 
  
  
you can check my blood 
pressure and general 
health 
 
  
  
 
I agree that you can put the 
sponge in my mouth 
 
 
 
 
  
  
 
I agree to have a blood test 
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Please tick no      or yes      for each part 
  
  
you can send my blood or 
spit to other researchers – 
they will not know my name 
 
  
  
you can store my test results 
on a computer 
 
  
  
you can share my test 
results with other 
researchers – they will not 
know my name 
  
  
you can share my test 
results with my doctor  
  
  
you can share my test 
results with my care team 
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Please tick no      or yes      for each part 
  
  
you can keep my blood or 
spit in the laboratory for 
more tests  
  
  
I want to know my test 
results  
 
  
  
you can get in touch with 
me again if you need to 
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 1 copy will be given to the participant 
 1 copy will be kept by the researcher 
 1 copy will be stored in the medical file 
 
 
 
 
 
 
 
 
 
 
my name my signature 
 
 
 
 
 
 
 date 
 
 
 
 
 
 researcher’s name their signature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
date 
 
name 
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Consultee Consent form 
Participant Identification Number: 
 
      
 
As someone who knows ________________ (person’s name) well/in an 
independent capacity, you are being invited to consider whether 
_____________ (person’s name) who lacks capacity, would want to 
participate in the research study based on your knowledge of him/her.    
We ask you to be a consultee because ______________ (person’s 
name) is unable to understand the information provided in the 
information leaflet or is unable to make independent decisions and 
communicate them.   
It is up to you to decide whether or not they would want to take part 
based on your knowledge of the person and the information you have 
been given.  Be reassured that even if you decide that they can take 
part, he/she is still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take 
part, will not affect any aspects of care. 
  
Please initial if 
you agree 
I have read the information sheet about the research. I 
have had chance to ask questions and talk about this 
study. I have got enough information about this study. 
 
I confirm that I have agreed to act as a consultee for 
the above named person. I understand that my role as 
consultee is to advise the research team as to the 
above named persons' likely wishes and feelings in 
relation to entering the study. 
 
I understand that the participant can stop taking part in 
this study at any time and does not have to give a 
reason. I understand that participation in the study will 
 
A study about how different areas of the brain work in 
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not change the help that the participant receives. 
 
Are you aware of any advance directives that may be 
relevant to participation in this research? 
If yes, please detail further: 
 
 
Yes/No 
 
 
 
  
Please initial if 
you agree 
It is appropriate for ______________ to participate in 
this study  
 
It is appropriate for______________ to have their 
blood pressure and general health checked 
 
It is appropriate for______________ to give a sample 
of saliva for genetic analysis 
 
It is appropriate for______________ to have a blood 
test for genetic and biomarker analysis 
 
I agree that their blood, saliva or DNA can be sent to 
other researchers (this will be anonymised) 
 
I agree that their samples can be stored for use in 
future research 
 
I agree that their test results can be stored on a 
database 
 
I agree that their test results can be shared with other 
researchers, including publically accessible databases 
(this will be anonymised) 
 
It is appropriate for the researcher to 
discuss__________ with their care team and send 
them a summary of the findings 
 
It is appropriate for the researcher to send their GP a  
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summary of the findings 
 
It is appropriate for the researcher to 
send___________ a summary of the findings 
 
It is appropriate for the researcher to get in touch with 
the participant again if they need to 
 
 
Any further comments or preferences from the consultee: 
 
 
 
Signed:      Name in Block Letters: 
 
Date:      Relation to participant: 
 
Researcher’ signature:    Name in Block Letters: 
 
Date:  
 
 
 1 copy will be given to the participant 
 1 copy will be given to the consultee 
 1 copy will be kept by the researcher 
 1 copy will be stored in the medical file 
 
 
184 
Data Collection form 
Assessing specific cognitive deficits associated with 
dementia in older adults with Down’s syndrome: a 
London based study 
Participant name  
Participant address  
Participant telephone number  
Informant name  
Relationship to participant  
Consultee name  
Consultee address  
Consultee telephone number  
Participant GP name  
Participant GP address  
Participant identification number  
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Participant Identification Number  
Date of assessment  
Referral centre  
Gender  
Age  
Level of learning disability  
Type of Accommodation (independent 
living, supported accommodation etc.) 
 
Ethnic origin  
  
Capacity to consent to study  
Capacity to consent to DNA sample  
Relationship of informant to participant  
Frequency of contact between 
informant and participant  
 
  
Premorbid IQ level   
Genetic diagnosis Down’s syndrome  
Family history Down’s syndrome  
Family history dementia  
  
Diagnosis of dementia   
Type of dementia  
Date of diagnosis  
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Physical Examination:   
 Blood Pressure  
 Pulse  
 Height  
 Weight  
 Abdominal 
circumference 
 
 Neurological findings: 
 
 
  
Medical problems:   
 Thyroid problems  
 Epilepsy  
 Date epilepsy started  
 History of stroke  
 History of head injury  
 Falls  
 Congenital 
cardiovascular 
problems 
 
 Diabetes  
 Smoker  
 Other  
  
Sensory problems:  
 Hearing  
 Date hearing problems 
started 
 
 Visual problems  
 Date visual problems 
started 
 
 Using any corrective 
methods 
 
  
Psychiatric history:  
 Psychosis (active or 
treated) 
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 Bipolar disorder  
 Depression  
 Date of last episode  
 How many episodes  
 Other  
 
 
 
Medication: 
 
 
 
Supplements (eg. Vitamins)  
  
Recent investigations:  
 Full Blood count  
 Thyroid tests  
 B12 levels  
 ECG  
 EEG  
 Head scan  
 Other  
  
 
Any other relevant information: 
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Table A1 – Skewness and Kurtosis of the cognitive tests 
 Dementia No Dementia 
 Skewness Kurtosis Skewness Kurtosis 
K-BIT II - Total raw score 2.817 9.101 0.731 -1.058 
K-BIT II - Verbal subscale  2.828 9.789 0.884 -0.538 
K-BIT II - Non verbal 
subscale  
2.073 3.978 0.575 -1.401 
CANTAB tests:     
CANTAB PAL first trial 
memory score 
1.404 2.097 1.677 2.744 
CANTAB PAL stages 
completed 
0.463 0.545 0.791 -0.579 
CANTAB IED – Stages 
completed 
0.941 -0.785 0.913 -0.971 
IED – Errors block 1 -0.230 -1.362 0.042 -1.805 
Modified dots task – 2nd 
stage 
-0.903 1.606 0.664 -1.068 
Modified dots task – 3rd 
stage 
-0.397 -1.081 0.498 1.724 
CANTAB SRT -0.151 -1.448 0.500 -0.836 
Finger sequencing task 1.272 1.819 1.193 0.377 
NEPSY visuomotor 
precision – Train and Car 
-0.332 -1.445 -1.44 -1.264 
NEPSY visuomotor 
precision – Car and 
Motorbike 
1.563 3.759 0.939 -0.457 
Table top tests:     
Verbal Fluency Raw score 0.797 0.396 0.643 0.496 
Verbal Fluency Adjusted 0.113 -0.856 -0.017 0.627 
Tower of London - Stages 
succeeded on 
-0.160 -1.694 0.146 -0.893 
Tower of London - Points 0.094 -1.444 0.496 -0.990 
Object Memory 0.361 -0.656 -0.488 -0.156 
Memory for sentences 0.081 -0.885 0.984 -0.013 
Finger-nose 0.514 -0.566 0.868 0.253 
Gait 0.079 -0.126 0.571 -0.624 
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Table A2 – Floor and ceiling levels of K-BIT II according to level of intellectual disability 
 Level of ID Dementia No Dementia 
  Number at floor (%) Number at ceiling (%) Number at floor (%) Number at ceiling (%) 
K-BIT II total raw score Mild 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 Moderate/ Severe 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
K-BIT II verbal subscale  Mild 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 Moderate/ Severe 1 (11.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
K-BIT II non verbal subscale  Mild 1 (20.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 
 Moderate/ Severe 3 (33.3%) 0 (0.0%) 2 (15.4%) 0 (0.0%) 
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Table A3 – Floor and ceiling levels of ACTB tests according to level of intellectual disability 
 
 Level of ID Dementia No Dementia 
  Number at floor (%) Number at ceiling (%) Number at floor (%) Number at ceiling (%) 
CANTAB PAL first trial 
memory score 
Mild 2 (66.7%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 
 Moderate/ Severe 3 (42.9%) 0 (0.0%) 5 (41.7%) 0 (0.0%) 
CANTAB PAL stages 
completed 
Mild 2 (66.7%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 
 Moderate/ Severe 1 (14.3%) 0 (0.0%) 1 (8.3%) 0 (0.0%) 
CANTAB IED stages 
completed 
Mild 2 (50.0%) 0 (0.0%) 2 (25.0%) 0 (0.0%) 
 Moderate/ Severe 4 (66.7%) 0 (0.0%) 5 (41.7%) 0 (0.0%) 
CANTAB IED errors block 1 Mild n/a 1 (25.0%) n/a 2 (25.0%) 
 Moderate/ Severe n/a 0 (0.0%) n/a 1 (8.3%) 
Modified dots task 2
nd
 stage Mild 2 (66.7%) 0 (0.0%) 3 (37.5%) 3 (37.5%) 
 Moderate/ Severe 4 (100%) 0 (0.0%) 7 (87.5%) 0 (0.0%) 
Modified dots task 3
rd
 stage Mild 2 (66.7%) 0 (0.0%) 4 (50.0%) 0 (0.0%) 
 Moderate/ Severe 4 (100%) 0 (0.0%) 7 (87.5%) 0 (0.0%) 
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 Level of ID Dementia No Dementia 
  Number at floor (%) Number at ceiling (%) Number at floor (%) Number at ceiling (%) 
CANTAB SRT median 
latency 
Mild n/a n/a n/a n/a 
 Moderate/ Severe n/a n/a n/a n/a 
Finger sequencing task Mild 1 (33.3%) 0 (0.0%) 0 (0.0%) 2 (28.6%) 
 Moderate/ Severe 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (8.3%) 
NEPSY visuomotor 
precision train and car 
Mild 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 Moderate/ Severe 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
NEPSY visuomotor 
precision car and motorbike 
Mild 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 Moderate/ Severe 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 
  Table A3 continued – Floor and ceiling levels of ACTB tests according to level of intellectual disability 
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Table A4 – Floor and ceiling levels of table top tests according to level of intellectual disability 
 Level of ID Dementia No Dementia 
  Number at floor (%) Number at ceiling (%) Number at floor (%) Number at ceiling (%) 
Verbal fluency raw score Mild 1 (33.3%) n/a 0 (0.0%) n/a 
 Moderate/ Severe 2 (33.3%) n/a 1 (8.3%) n/a 
Verbal fluency adjusted Mild 1 (33.3%) n/a 0 (0.0%) n/a 
 Moderate/ Severe 2 (33.3%) n/a 1 (8.3%) n/a 
Tower of London stages 
completed 
Mild 3 (75.0%) 0 (0.0%) 0 (0.0%) 5 (71.4%) 
 Moderate/ Severe 2 (28.6%) 0 (0.0%) 1 (9.1%) 0 (0.0%) 
Tower of London points Mild 3 (75.0%) 0 (0.0%) 1 (14.3%) 2 (7.4%) 
 Moderate/ Severe 3 (42.9%) 0 (0.0%) 4 (36.4%) 0 (0.0%) 
Object memory Mild 2 (50.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 Moderate/ Severe 4 (57.1%) 0 (0.0%) 0 (0.0%) 2 (18.2%) 
Memory for sentences Mild 1 (25.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 Moderate/ Severe 1 (14.3%) 0 (0.0%) 1 (8.3%) 0 (0.0%) 
Finger-nose Mild 0 (0.0%) n/a 0 (0.0%) n/a 
 Moderate/ Severe 0 (0.0%) n/a 0 (0.0%) n/a 
Gait assessment Mild 1 (33.3%) n/a 0 (0.0%) n/a 
 Moderate/ Severe 1 (14.3%) n/a 0 (0.0%) n/a 
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